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Fabry disease is a rare, X-linked lysosomal storage disease arising from deficiency of 
the lysosomal hydrolase, α-galactosidase A (GLA). Reduced GLA activity disrupts 
glycosphingolipid (GSL) catabolism, leading to widespread accumulation of neutral 
GSLs in cells resulting in clinical manifestations such as stroke, vasculopathy, 
cardiomyopathy, and renal failure. The link between GLA deficiency and accumulation 
of GSLs with vascular dysfunction is unclear. Past work in the Shayman lab has led to 
the formulation of an overarching hypothesis for the mechanism of the vasculopathy in 
Fabry disease, namely that GLA deficiency leads to uncoupling of endothelial nitric 
oxide synthase (eNOS) and formation of reactive oxidants resulting in protein 
nitrosylation. The primary cause of eNOS uncoupling in the setting of GLA deficiency is 
unknown. 
In this thesis, I used the CRISPR/Cas9 method for gene editing to mutate Gla in the 
human endothelial cell line, EA.hy926, to obtain GLA-deficient cells. Neutral GSLs were 
extracted and analyzed with thin layer chromatography (TLC). NOS activity was 
measured by monitoring the conversion of [3H]L-arginine to [3H]L-citrulline. Contrary to 
what is observed with siRNA knockdown of GLA expression in EA.hy926 cells, GLA-
deficient cells did not accumulate the primary substrate for GLA, globotriaosylceramide 
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(Gb3). On the other hand, further analysis showed that these GLA-deficient cells 
accumulate the downstream GSL, globotetraosylceramide (Gb4). However, both the 
siRNA and CRISPR/Cas9 models have elevated globotriaosylsphingosine (lyso-Gb3). 
As observed with siRNA knockdown of GLA expression, CRISPR/Cas9 GLA-deficient 
cells had less NOS activity. Two different methods of reducing globo series GSLs had 
opposite effects on NOS activity. Restoring GLA activity in GLA-deficient cells with 
exogenous GLA treatment improved NOS activity. In contrast, treating cells with a 
glucosylceramide synthase inhibitor (inhibits the synthesis of downstream GSLs) 
decreased NOS activity. These results suggest that eNOS uncoupling is due to GLA 
deficiency, and not necessarily due to elevated GSLs. Other studies showed that NOS 
activity is improved in GLA-deficient cells by increasing the availability of the eNOS 
cofactor, tetrahydrobiopterin, suggesting that GLA-deficient cells have a limited supply 






Chapter 1: Introduction 
Fabry Disease 
Fabry disease (OMIM 301500) is a rare lysosomal storage disease caused by a 
deficiency in the lysosomal hydrolase, α-galactosidase A (GLA, EC 3.2.1.22). GLA 
cleaves terminal α-galactosyl sugar groups. The primary substrate for GLA is the neutral 
glycosphingolipid (GSL), globotriaosylceramide (Gb3). Loss of GLA function results in 
progressive accumulation of Gb3 in various cells and tissues. Gla is located on the X 
chromosome (Xq22.1), which results in the disease primary affecting males, although 
heterozygous females also experience complications (Anderson 1898, Fabry 1898, 





Figure 1.1: Synthesis and degradation of some globo-series GSLs. Fabry 
disease is caused by deficient GLA activity. GLA degrades Gb3 to LacCer. 
Deficient β-glucocerebrosidase (GBA) activity causes Gaucher disease, another 
lysosomal storage disease. 
 
The pathogenesis of the cardiovascular complications of Fabry disease is not well 
understood. Past clinical studies (Moore, Scott et al. 2001, Moore, Ye et al. 2004) and 
mouse studies in the Shayman group (Shu, Park et al. 2009, Kang, Shu et al. 2014, 
Shu, Vivekanandan-Giri et al. 2014) have reported that GLA deficiency causes 
dysregulation of nitric oxide (NO) production and increased production of oxidant 
species. Nitrotyrosine, a product of protein nitrosylation, is elevated in patients with 
Fabry disease, GLA-deficient mice, and in vitro models of Fabry disease (Shu, 
Vivekanandan-Giri et al. 2014). Nitrotyrosine is a product of peroxynitrite, which is 
produced by uncoupling of endothelial nitric oxide synthase (eNOS) (Heinecke 2002). 
The link between GLA deficiency and eNOS uncoupling is not clear.  
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History and discovery 
Fabry disease was first described as “angiokeratoma corporis diffusum” in 1898, by the 
two physicians, Johannes Fabry and William Anderson (Anderson 1898, Fabry 1898). It 
was originally described as a skin condition because the most prominent finding in 
patients was skin lesions on the hands and feet.  
Thickening of blood vessel walls and enlargement and pronounced vacuolization of 
smooth muscle cells was observed in the first autopsy of a patient with Fabry disease, 
performed in 1945. It was suggested that the vasculopathy was due to accumulation of 
a material that could not be stained between muscle fibers. Autopsies of other patients 
a few years later showed accumulation of a lipoid-like substance in blood vessel walls, 
smooth muscle cells, cardiac muscle fibers, ganglion cells in the brain, and the 
peripheral nervous system (Ruiter 1957). 
The main lipid that accumulates in Fabry disease was determined to be Gb3 (GL-3), 
and to a lesser extent, galabiosylceramide (GL-2) (Sweeley and Klionsky 1963). In 
1965, GLA deficiency was reported to have X-linked inheritance (Opitz, Stiles et al. 
1965). The enzymatic defect contributing to Gb3 accumulation was attributed to a 
deficiency of ceremidetrihexosidase (GLA) activity in 1967 (Brady, Gal et al. 1967). 
The Gla gene is located on Xq22.1, is 12 kilobases long, and has 7 exons that translate 
to 429 amino acids (Bishop, Kornreich et al. 1988). The functioning GLA enzyme is a 
homodimer, with each monomer containing 398 residues (Garman and Garboczi 2004). 
GLA undergoes post-translational modification by N-glycosylation of three residues of 
each monomer (Matsuura, Ohta et al. 1998). The glycosylation pattern varies by tissue 
and affects the solubility (Ioannou, Zeidner et al. 1998) and stability of GLA (Lemansky, 
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Bishop et al. 1987), as well as trafficking of GLA to the lysosome, via the mannose-6-
phosphate receptor (Chiba, Sakuraba et al. 2002). 
Epidemiology, symptoms, and diagnosis 
Reports of the occurrence of the disease vary, but some sources say Fabry disease is 
found in 43,000-117,000 males. One survey of newborns indicated that 1 in 3100 males 
have a GLA mutation (Spada, Pagliardini et al. 2006). Over 300 GLA mutations have 
been reported (Garman 2007). Because it is a rare disease, and presenting symptoms 
could be attributed to other causes, it is often not diagnosed until later in life. The 
prevalence may be underestimated (Colon, Ortolano et al. 2017). A study of 366 
patients revealed a 13.7 and 16.3 year gap for males and females, respectively, 
between age of onset of symptoms and diagnosis of Fabry disease (Mehta, Ricci et al. 
2004). A study of 1765 patients revealed that the median ages of diagnosis for males 
and females were 23 and 32, respectively, but the onset of symptoms were at age 9 
and 13, respectively (Eng, Fletcher et al. 2007). 
GLA deficiency results in an accumulation of neutral GSLs, leading to cellular and organ 
dysfunction. Poor perfusion due to accumulated GSLs may contribute to symptoms. 
Symptoms in early childhood include neurological pain, hyperhidrosis or hypohidrosis, 
angiokeratomas, gastrointestinal issues, and abnormal facial features. However, deaths 
usually arise from end-stage renal disease and premature stroke (Sims, Politei et al. 
2009). 
Fabry disease is diagnosed by measuring GLA activity in plasma or isolated leukocytes. 
This method is more reliable for males because heterozygous females have one 
functional copy of Gla, resulting in GLA activity in the normal range. Therefore, in 
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females, genetic testing is the preferred diagnostic method. Residual enzyme activity 
can slow the progression of the disease, resulting in the late-onset, cardiac and renal, 
variants (Spada, Pagliardini et al. 2006). As little as 5-10% of normal GLA enzyme 
activity may prevent accumulation of Gb3 and disease progression (Clarke 2007). 
In males, early clinical symptoms of the disease include neuropathic pain (burning 
sensation in hands and feet), angiokeratomas (reddish-purple skin lesions), 
hypohidrosis, abdominal pain, gastrointestinal issues, and corneal opacities and 
cataracts in the eye. Later in life, as more Gb3 accumulates, patients experience renal 
disease and cardiovascular dysfunction (Desnick, Ioannou et al. 2001). By years 35-45, 
most male patients will require a kidney transplant or dialysis (Branton, Schiffmann et al. 
2002, Thadhani, Wolf et al. 2002). Life expectancy in males is reduced by 20 years 
(MacDermot, Holmes et al. 2001), and in females by 15 years (MacDermot, Holmes et 
al. 2001). 
Although Fabry disease has X-linked inheritance, heterozygous females can still 
develop symptoms of the disease. However, clinical manifestations are variable due to 
random X-chromosomal inactivation (Willard 2001, Morrone, Cavicchi et al. 2003, 
Dobrovolny, Dvorakova et al. 2005). Symptoms often present between ages 30 to 50. 
These include non-life-threatening (e.g. angiokeratomas) and life-threatening (e.g. left 
ventricular hypertrophy) manifestations (Kampmann, Baehner et al. 2002). In some 
female patients, the disease can be as severe as that seen in males (Desnick, Simmons 
et al. 1972). 
Cardiac manifestations in patients include thickening of left heart valves, left ventricular 
hypertrophy, electrocardiographic abnormalities, and arrhythmias (Zarate and Hopkin 
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2008). Gb3 accumulates in endothelial and cardiac muscle cells, which leads to 
vascular dysfunction and structural changes (Linhart and Elliott 2007). However, there 
are some conflicting reports regarding blood flow and peripheral endothelial function. 
Altarescu and colleagues reported that forearm blood flow and acetylcholine responses 
were elevated in patients with Fabry patients compared to control subjects (Altarescu, 
Moore et al. 2001). Several clinical studies report an increase in intima-media thickness 
and flow-mediated dilatation (Boutouyrie, Laurent et al. 2001, Boutouyrie, Laurent et al. 
2002, Kalliokoski, Kalliokoski et al. 2006), while others report no change in radial artery 
wall thickness (Moore, Altarescu et al. 2002) and decreased flow-mediated dilatation 
(Kalliokoski, Kalliokoski et al. 2006). Increased cerebrovascular blood flow has been 
observed in Fabry patients (Moore, Altarescu et al. 2002). Autopsies of Fabry patients 
have shown no atherosclerotic lesions (Elleder 2003), or many atherosclerotic lesions 
(Schiffmann, Rapkiewicz et al. 2006). Clearly, Fabry disease has a complicated 
pathology that varies from person to person. 
Treatment 
Because Fabry disease is a multi-organ disease, managing symptoms is a part of 
treatment (Eng, Germain et al. 2006). In the United States, the only therapeutic to treat 
the underlying cause is enzyme replacement therapy (ERT) with recombinant GLA. Two 
forms of ERT are approved for use to treat Fabry disease, agalsidase alfa (Replagal™, 
Shire) and agalsidase beta (Fabrazyme™, Genzyme) (Vedder, Linthorst et al. 2007). 
ERT was FDA-approved in 2003 for use in the United States, and EMA-approved in 
2001 for use in the European Union (Eng, Banikazemi et al. 2001, Eng, Guffon et al. 
2001, Schiffmann, Kopp et al. 2001, Wilcox, Banikazemi et al. 2004). Based on clinical 
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trials, ERT is the standard of care as it has been shown to clear Gb3 from kidney cells 
(Thurberg, Rennke et al. 2002) and reduce renal, cardiac, and CNS events 
(Banikazemi, Bultas et al. 2007). ERT has been shown to improve neuropathic pain 
(Schiffmann, Kopp et al. 2001). Two studies have reported ERT decreases left 
ventricular mass (Weidemann, Breunig et al. 2003, Hughes, Elliott et al. 2008), while 
another has shown no improvement (Vedder, Linthorst et al. 2007). However, ERT does 
not lower the risk of cardiovascular events, unless ERT is initiated before any major 
event (Hopkin, Cabrera et al. 2016). 
ERT has limitations in improving the clinical manifestations of Fabry disease. First, 
infusions are administered on a weekly or bi-weekly basis, which may be insufficient for 
Fabry patients to have normal, consistent, GLA activity (Schiffmann, Askari et al. 2007). 
Second, patients may develop an immune reaction to the infused enzyme, which can 
decrease the efficacy (Linthorst, Hollak et al. 2004, Rombach, Aerts et al. 2012). Third, 
when ERT is started after there has been organ damage, ERT does not halt disease 
progression. The earlier in life a patient starts ERT, the less likely they are to experience 
major complications from the disease (Cabrera, Politei et al. 2017), and the more likely 
they are to have reduction in globotriaosylsphingosine (lyso-Gb3), the deacylated 
metabolite of Gb3 (Arends, Wijburg et al. 2017), which will be discussed later. There is 
a need to better understand the pathology of GLA deficiency to develop a better 
treatment plan to improve the long-term effects of GLA deficiency that ERT alone 
cannot improve. 
An alternative treatment, substrate reduction therapy, was proposed by Norman Radin 
in 1972 for treating lysosomal storage diseases (Radin, Arora et al. 1972). Inhibiting 
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sphingolipid synthesis can counteract the effect of a deficient catabolic enzyme. In 
Gaucher disease, the deficient lysosomal hydrolase is β-glucocerebrosidase, GBA (fig. 
1.1), which degrades GlcCer to ceramide. Therefore, preventing synthesis of GlcCer by 
inhibiting GlcCer synthase would reduce the amount of accumulating GlcCer. An 
inhibitor for this enzyme, eliglustat tartrate (Cerdelga®, Genzyme), was developed in 
the Shayman lab, and was FDA approved in August 2014 for the treatment of Gaucher 
disease. It has since been approved for use in Europe, Australia, Japan, and Canada. 
Because at the time there was no suitable Gaucher mouse model, proof-of-concept 
studies with glucosylceramide synthase inhibitors were performed with the mouse 
model for Fabry disease (Abe, Arend et al. 2000, Abe, Gregory et al. 2000). GlcCer 
synthase inhibitors decrease the accumulation of lactosylceramide (LacCer), Gb3, and 
globotetraosylceramide (Gb4) (fig. 1.2), because GlcCer is a precursor for synthesis of 
these downstream GSLs. Treatment with the GlcCer synthase inhibitor, EtDO-P4, was 
able to reduce GlcCer and Gb3 content in cultured lymphocytes from Fabry patients, 
and in kidney, liver, and heart of GLA-deficient mice (Shayman and Larsen 2014).  
Another therapeutic approach is chaperone therapy, which enhances residual enzyme 
activity by preventing misfolding and degradation of the mutated enzyme (Frustaci, 
Chimenti et al. 2001). Eligibility for this oral treatment is based on the specific Gla 
mutation a patient carries (Benjamin, Della Valle et al. 2017). The molecular chaperone 
migalastat (Galafold™, Amicus Therapeutics) was approved for use in Europe in 2016 
(Germain, Hughes et al. 2016).  
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Globo series glycosphingolipids 
Glycosphingolipids (GSLs) are molecules composed of a ceramide group and 
carbohydrate. A ceramide is made up of a fatty acid group with an amide linkage to a 
long-chain base, sphingosine. The carbohydrate has a glycosidic linkage to the primary 
hydroxyl group of the sphingosine. GSLs have both hydrophobic and hydrophilic 
properties. De novo formation of ceramide begins with the condensation of palmitoyl-
CoA and serine by serine palmitoyltransferase (Brady and Koval 1958) and is followed 
by reduction and acylation enzymatic reactions, utilizing NADPH and acyl-CoAs 
(Sribney 1966). Ceramide is utilized by several catabolic pathways. It can be used to 
make phosphatidylcholine and sphingomyelin. Ceramide may be phosphorylated to 
form ceramide-1-phosphate. Another pathway ceramide is a precursor for is GSLs, 
resulting from glycosylation of ceramide. There are two classes of GSLs, neutral and 
acidic, based on the charge of the carbohydrate moiety. The following will further 
describe a class of neutral GSLs, the globo-series GSLs (structures shown in fig. 1.2). 
The single-sugar GSLs, cerebrosides, are glucosylceramide (GlcCer) and 
galactosylceramide (GalCer). GlcCer is synthesized by UDP-glucose:ceramide 
glycosyltransferase from ceramide and UDP-glucose. GlcCer is further glycosylated to 
form lactosylceramide (LacCer, ceramide dihexoside, CDH), globotriaosylceramide 
(Gb3, ceramide trihexoside, CTH) (Makita and Yamakawa 1962, Makita 1964), and 
globotetraosylceramide (Gb4, globoside). 
As previously described, the primary substrate for GLA is Gb3. Gb3 is a neutral 
glycosphingolipid that is a blood antigen. Gb3 is the receptor for verotoxin (shiga-like 
toxin), which is the toxin from E. coli causing hemolytic uremic syndrome  (Karmali, 
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Petric et al. 1985, Lindberg, Brown et al. 1987). Gb3 is the blood group PK antigen 
(Marcus, Naiki et al. 1976). Gb3 is comprised of a ceramide base, sphingosine, and the 
three sugar groups, glucose, galactose, and galactose. It is synthesized from LacCer by 
Gb3 synthase (Gb3/CD77 synthase, α1,4Gal-T) in the cytoplasm (Taga, Mangeney et 
al. 1995), and transported to the lysosome to be degraded by GLA. Although GLA is 
active in the lysosome, Gb3 accumulates outside of the lysosome in the cell membrane 
(Askari, Kaneski et al. 2007, Shu and Shayman 2007). 
Although Gb3 is the primary substrate for GLA, it is not a reliable marker for severity of 
disease manifestations. Some Fabry patients do not have elevated Gb3 before 
beginning ERT (Young, Mills et al. 2005). There is no correlation between individual 
symptoms and urinary or plasma Gb3 levels of patients, or a decrease in plasma Gb3 
after ERT, even with clinical improvement  (Young, Mills et al. 2005, Vedder, Linthorst et 
al. 2007). However, in non-Fabry patients, there is a correlation between urinary Gb3 
levels and risk of heart diseases (Schiffmann, Forni et al. 2014).  
LacCer is formed by the degradation of Gb3 by GLA, or de novo synthesis by LacCer 
Synthase (β1,4-GalT family). LacCer synthase activity and LacCer levels are elevated in 
patients with familial hypercholesterolemia and atherosclerosis (Chatterjee, Sekerke et 
al. 1982, Chatterjee, Dey et al. 1997). LacCer has been shown to be a second 
messenger, and to stimulate the production of superoxide and other signaling 
mechanisms (Chatterjee 1998). 
Gb4 is synthesized from Gb3 by β1,3-N-acetylgalactosaminyltransferase (β1,3GalNAc-
T, Gb4 Synthase, Gb4S).  Gb4 is the major neutral GSL of senescent erythrocytes, and 
is a major source for circulating Gb3 (Dawson and Sweeley 1970). Gb4 is the blood 
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group P antigen (Naiki and Marcus 1974, Naiki and Marcus 1975, Marcus, Naiki et al. 
1976). 
Lyso-Gb3 (globotriaosylsphingosine) is a deacylated form of Gb3. Acid ceramidase 
found in lysosomes metabolizes excess Gb3 to lyso-Gb3. Lyso-Gb3 is more water-
soluble and is more easily excreted, providing a potential elimination pathway for Gb3 
(Ferraz, Marques et al. 2016). Lyso-Gb3 is found in plasma of patients with Fabry 
disease (195-407 nM in affected males). Several studies suggest a link between lyso-
Gb3 and Fabry disease, both as a biomarker and a cause for inflammation. In Fabry 
patients, a correlation exists between lyso-Gb3 (deacylated Gb3) and clinical 
manifestations (Rombach, Dekker et al. 2010). In many cases, heterozygous females 
have normal circulating levels of GLA, but still experience symptoms of the disease. 
Lyso-Gb3 may be a better marker for heterozygous females as it has been shown that 
symptomatic heterozygotes had elevated plasma lyso-Gb3 (22-76 nM) while lyso-Gb3 
was not detected in an asymptomatic heterozygote. There have been similar findings in 
GLA-deficient mice (Aerts, Groener et al. 2008). Lyso-lipids found to be elevated in 
other lipid storage diseases, Krabbe disease (galactosylsphingosine), and Gaucher 
disease (glucosylsphingosine), have been shown to have toxic effects (Tanaka and 
Webster 1993, Schueler, Kolter et al. 2003). 
Lyso-Gb3 has been shown to promote smooth muscle cell proliferation, which may 
contribute to the increased intima-media thickening seen in patients; Gb3 and 
lactosylsphingosine do not exhibit the same effect. ERT can reduce lyso-Gb3 in plasma 
(Aerts, Groener et al. 2008, Rombach, Dekker et al. 2010, van Breemen, Rombach et 




Figure 1.2: Structures of the globo-series GSLs. GSLs are composed of a 
carbohydrate and ceramide. Ceramide is made up of a fatty acid group with an 
amide linkage to a long-chain base, sphingosine. The length of the fatty acid acyl 
chain varies between 16 and 24 carbons. glucosylceramide (GlcCer); 
lactosylceramide (LacCer); globotriaosylceramide (Gb3); globotetraosylceramide 
(Gb4); globotriaosylsphingosine (Lyso-Gb3). 
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In vivo Fabry disease model: Gla-knockout Mouse 
In order to elucidate pathological mechanisms behind the clinical manifestations of 
Fabry disease, both in vivo and in vitro models of GLA-deficiency have been used.  
The Gla knockout mouse (Ohshima, Murray et al. 1997) exhibits accumulation of lipids 
with terminal α-D-galactosyl moieties, mainly Gb3, in the liver and kidneys. GSL 
accumulation is also seen in cultured fibroblasts, and is corrected upon transfection with 
human GLA cDNA. The mice do not show any phenotypic changes before 10 weeks of 
age. Despite the accumulation of neutral GSLs in organs, the GLA-deficient mice differ 
from human Fabry patients in that they do not display renal failure until 80 weeks of 
age, nor do they have a spontaneous vascular phenotype. Red blood cells in GLA-
deficient mice and humans show elevated amounts of Gb3 and Gb4 (Ohshima, 
Schiffmann et al. 1999). 
Despite accumulating Gb3 in the vasculature, Gla-knockout mice do not display an 
obvious vascular abnormality. Previous studies in the Shayman group have utilized 
inducible models of vasculopathy to uncover defects in vascular function in Gla-
knockout mice, specifically that deficiency of GLA leads to increased incidence of 
arterial thrombosis (Eitzman, Bodary et al. 2003), accelerated atherogenesis (Bodary, 
Shen et al. 2005), impaired vasorelaxation in both large and small arteries (Park, 
Whitesall et al. 2008, Kang, Shu et al. 2014), and a decrease in nitric oxide (NO) 
bioavailability arising from less activity of endothelial nitric oxide synthase (eNOS) (Shu, 
Park et al. 2009). The following is a more detailed description of these experiments. 
Results from the following experiments led to the hypothesis that cardiovascular 




A study was performed comparing time to occlusion in the carotid artery of Gla-/0 and 
Gla+/0 mice (hemizygous and wild type male, respectively), using a common model to 
study thrombosis, where time to occlusion is measured following rose bengal injection 
and exposure of the carotid artery to a green laser light (Eitzman, Bodary et al. 2003). 
The laser causes the local release of reactive oxygen species and subsequent damage 
to the endothelium. A thrombus forms at the site of endothelial damage, and the time to 
occlusive thrombus formation is a measure of the thrombotic nature of the system being 
examined. The results indicated an age-dependent decrease in time to occlusion of the 
Gla-/0 mice that was not corrected upon bone marrow transplantation from Gla+/0 mice, 
indicating the defect is localized to the vascular wall. 
Accelerated atherogenesis 
A study was performed where both male and female Gla-knockout and WT mice were 
bred on an ApoE-/- background (Bodary, Shen et al. 2005), which is a common model to 
study atherogenesis (Zhang, Reddick et al. 1992). After mice were fed on a Western 
chow diet, the aortas from Gla-knockout/ApoE-knockout mice had significantly greater 
lesion areas compared to GLA-WT controls bread on ApoE-/- background. In addition, 
the aortas from GLA-deficient mice had more iNOS and nitrotyrosine staining, which are 
markers for atherosclerosis. Accumulation of Gb3 in the vessel wall correlated with 
these markers. The conclusion was that GLA deficiency promotes atherosclerosis. 
Impaired vasoreactivity 
The vascular abnormalities described in the previous two experiments indicate a 
change in the arterial wall of mice lacking GLA. Because both defects could be due to 
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changes in nitric oxide production, it was important to determine how GLA-deficiency 
affects the endothelium where NO production occurs. Therefore, vascular aortic rings 
were isolated from Gla-/0 and Gla+/0 mice, exposed to phenylephrine to contract them, 
and then subjected to increasing concentrations of acetylcholine (a vasodilator) (Park, 
Whitesall et al. 2008). The relaxation response was drastically reduced in rings from 
Gla-/0 mice, indicative of impaired acetylcholine-induced NO production. A subsequent 
study investigated endothelial dysfunction in the mesenteric arteries from GLA-deficient 
mice and reported impaired relaxation of vessels to acetylcholine and evidence of 
eNOS uncoupling (Kang, Shu et al. 2014).  
In vitro Fabry disease models 
As described previously, GLA deficiency contributes to the accumulation of neutral 
GSLs in various cell types and organs. Notably, vascular endothelial cells are the most 
affected cell type (Desnick, Ioannou et al. 2001), which could explain the prevalence of 
stroke and cardiac abnormalities in patients. The three models of induced vasculopathy 
described in the previous section indicated a defect localized to the endothelium. To 
further investigate changes due to GLA deficiency, the Shayman group has utilized in 
vitro models to detect changes in endothelial cells. Results from the following 
experiments have led to the hypothesis that eNOS uncoupling is the basis for 
cardiovascular abnormalities in Fabry disease. 
Mouse aortic endothelial cells 
Mouse Aortic Endothelial Cells (MAECs) were isolated from aortas of Gla-/0 and Gla+/0 
mice (Shu, Murphy et al. 2005). The activity and expression of eNOS from cells from 
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Gla-/0 mice was decreased (Shu and Shayman 2007, Shu, Park et al. 2009). It was also 
shown that the composition of caveolae was changed; Gb3 accumulated in the 
caveolae of MAECs from Gla-/0 (Shu and Shayman 2007). Consequently, localization of 
eNOS to caveolae, one method of eNOS regulation, is disrupted. Decreased eNOS-
caveolar association decreases eNOS activity (Garcia-Cardena, Oh et al. 1996). 
Treatment with the GlcCer synthase inhibitor, D-threo-ethylenedioxyphenyl-2-
palmitoylamino-3-pyrrolidinopropanol, did not restore eNOS activity despite lowering the 
Gb3 content of GLA-deficient cells. These results are indicative of long-term 
consequences of GLA-deficiency that cannot be reversed by restoring Gb3 levels to 
normal levels (that of WT). 
The MAEC model provided valuable evidence for how GLA deficiency contributes to 
changes in eNOS expression and location in endothelial cells. However, the drawback 
of this model is the difficulty of establishing these primary cell lines and the limited 
number of passages that can be used. Therefore, a better, permanent endothelial cell 
line was needed. 
GLA-siRNA knockdown in EA.hy926 cells 
The EA.hy926 cell line is derived from the fusion of a human umbilical vein cord 
(HUVEC) cell with an A549 permanent human lung carcinoma cell (Edgell, McDonald et 
al. 1983). Cells retain properties of endothelial cells, including expression of eNOS, 
Weibel-Palade bodies, and von Willebrand factor. However, EA.hy926 cells have more 
chromosomes than do HUVEC and A549 cells, and retain a marker chromosome from 
A549 cells (Emeis and Edgell 1988, Edgell, Haizlip et al. 1990). These cells express 
GLA and were chosen to study eNOS uncoupling. GLA expression was silenced with 
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siRNA (Shu, Vivekanandan-Giri et al. 2014), and resulted in an accumulation of Gb3 
correlating with duration of siRNA treatment (either 3 or 6 days), and a decrease in NOS 
activity. siRNA targeting β-glucocerebrosidase (GBA) (fig. 1.1), the enzyme deficient in 
Gaucher disease, did not exhibit a change in NOS activity. Furthermore, a marker for 
eNOS uncoupling, 3-nitrotyrosine (Heinecke 2002), was found to be increased in GLA-
siRNA treated cells. This siRNA model was useful to characterize how even a 
temporary loss of GLA expression and/or increase in Gb3 content directly impacts 
eNOS activity. However, to determine long-term changes, a permanent, GLA-deficient 
cell line was needed. The work described in this dissertation uses EA.hy926 cells with 
permanent GLA deficiency (induced by CRISPR/Cas9-gene editing) to investigate 
changes in eNOS function. 
Fabry disease models: conclusions 
While studies using these models have each contributed to the overall understanding of 
Fabry disease, there are limitations for each. The Gla-knockout mouse was useful for 
studying the effects of GLA deficiency on intact tissue, but further investigations into 
changes at the cellular level was limited. The primary cell model using MAECs was 
useful for bridging the gap between in vivo and in vitro studies, but was difficult to 
isolate and maintain in cell culture. The EA.hy926 cell line is often used for studies in 
endothelial cells because it retains many endothelial cell characteristics and is of human 
origin (Bouis, Hospers et al. 2001). However, in order to induce a Fabry phenotype, 
siRNA silencing was used to knockdown GLA expression. This allowed for the 
discovery of elevated 3-nitrotyrosine as a result of GLA-deficiency, indicating the 
occurrence of eNOS uncoupling. However, siRNA transfection is limited by the length of 
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time the treatment is effective for, and by possible off-target effects. Therefore, the work 
presented in this dissertation uses the newer method of CRISPR/Cas9 gene editing to 
create cell lines with a permanent Gla mutation. To address possible off-target effects, 
cell lines were generated by targeting two different exons of Gla, and growing several 
single-cell colonies. 
The link between GLA deficiency and cardiovascular dysfunction is not clear. The 
primary hypothesis in the Shayman group is that GLA deficiency leads to endothelial 
nitric oxide synthase (eNOS) uncoupling resulting in less production of nitric oxide (NO) 
and increased production of oxidant species. 
Nitric oxide, eNOS, and eNOS uncoupling 
The reaction catalyzed by endothelial nitric oxide synthase (eNOS) is: L-arginine + O2 
 L-citrulline + NO, and is dependent on cofactors, nicotinamide adenine dinucleotide 
phosphate (NADPH), tetrahydrobiopterin (BH4), flavin mononucleotide (FMN), flavin 
adenine dinucleotide (FAD), heme, Ca2+, and calmodulin. 
Robert Furchgott discovered the critical role of an intact endothelium for acetylcholine-
induced relaxation of aortic rings (Furchgott and Zawadzki 1980). He determined that 
endothelial cells release a factor, endothelium derived relaxing factor (EDRF), which 
relaxes vascular smooth muscles cells, resulting in dilation of blood vessels. Later, 
Louis Ignarro identified EDRF as NO (Ignarro, Buga et al. 1987). Ferid Murad 
contributed to the field by identifying that many vasodilators act through NO (Pollock, 
Forstermann et al. 1991). These three individual were awarded the Nobel Prize in 
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Physiology or Medicine in 1998. NO was the first gas discovered to act as a second 
messenger (Nobelprize.org 1998). 
Abnormal endothelial function is a factor in the development of common vascular 
diseases, such as stroke and coronary artery disease. An important function of the 
endothelium is the production of NO by eNOS. NO is a critical regulator of vascular 
homeostasis. It inhibits platelet aggregation, vascular smooth muscle cell proliferation, 
and leukocyte adhesion (Ignarro 2002). NO can act within the cell or diffuse locally to 
signal a variety of physiology responses by generating secondary messengers. For 
example, NO inhibits contraction of smooth muscle cells and prevents thrombosis by 
stimulating the release of cGMP. NO also nitrosylates cysteine residues of proteins (S-
nitrosylation) (Stamler, Simon et al. 1992); for example, S-nitrosylation of N-
ethylmaleimide-sensitive factor (NSF) prevents exocytosis of Weibel Palade bodies 
(Matsushita, Morrell et al. 2003). Weibel Palade bodies contain the pro-thrombotic 
factor, von Willebrand factor (Reinders, De Groot et al. 1984). Therefore, the main result 
of NO in this system is preventing secretion of von Willebrand factor. 
There are three members of the NOS family, neuronal NOS (nNOS), inducible NOS 
(iNOS), and endothelial NOS (eNOS), named after the cell type from which they were 
discovered. eNOS is constitutively expressed in endothelial cells, but expression is 
regulated in response to various stimuli. For example, eNOS mRNA and protein 
expression increases when endothelial cells are exposed to shear stress (Nishida, 
Harrison et al. 1992). eNOS is post-translationally modified. It is N-myristoylated 
(Pollock, Klinghofer et al. 1992, Liu and Sessa 1994)  and palmitoylated (Liu, Garcia-
Cardena et al. 1995, Robinson, Busconi et al. 1995, Liu, Garcia-Cardena et al. 1996). 
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Several protein kinases regulate eNOS activity, including Akt, PKA, PKC, and AMP-
activated protein kinase (Chen, Mitchelhill et al. 1999, Fulton, Gratton et al. 1999, 
Michell, Griffiths et al. 1999, Michell, Chen et al. 2001). Phosphorylation can activate or 
inhibit eNOS function depending on the residue that is phosphorylated. Other factors, 
including vascular endothelial growth factor (VEGF), insulin-like growth factor-1 (IGF-1), 
and estrogen also affect eNOS activity (Xia, Aiello et al. 1996, Hisamoto, Ohmichi et al. 
2001). 
In addition to eNOS mRNA and protein expression and posttranslational modification, 
the bioavailability of NO is affected by the availability of the substrate, L-arginine, or 
cofactors, and protein-protein interactions such as caveolin-1 and heat shock protein 90 
(Hsp90) (Garcia-Cardena, Fan et al. 1998). An additional factor is the presence of 
superoxide. NO reacts with superoxide to yield peroxynitrite, which causes further 
oxidations, including the conversion of BH4 to BH2 (Huang 2009), resulting in eNOS 
uncoupling. 
A common observation with eNOS and vascular disease is that higher eNOS protein 
expression does not necessarily result in more NO production. eNOS expression is 
reduced in endothelial cells located over advanced atherosclerotic plaques (Wilcox, 
Subramanian et al. 1997). However, in diabetes, heart failure, and hypertension, eNOS 
expression remains normal or is increased (Bouloumie, Bauersachs et al. 1997, 
Cosentino, Hishikawa et al. 1997, Bauersachs, Bouloumie et al. 1999, Hink, Li et al. 




eNOS becomes uncoupled when electrons from NADPH in the reductase domain flow 
to molecular oxygen rather than to the oxygenase domain to reduce L-arginine (fig 1.3). 
This complex forms superoxide instead of NO (Vasquez-Vivar, Kalyanaraman et al. 
1998, Xia, Tsai et al. 1998). Superoxide can then react with NO to produce peroxynitrite 
(ONOO-). ONOO- is a reactive nitrogen species that can oxidize BH4 to the inactive 
form, BH2 (Milstien and Katusic 1999). A biomarker for the presence of ONOO- is 3-
nitrotyrosine resulting from protein nitrosylation (Heinecke 2002). A lower ratio of 
BH4:BH2 and eNOS:BH4 contributes to eNOS uncoupling (Crabtree, Tatham et al. 
2009). There are two main pathways of BH4 formation (fig 1.4), which can be 
pharmacologically manipulated to increase BH4 availability. 
eNOS uncoupling is a characteristic of common diseases with a vascular dysfunction 
component, like hypercholesterolemia (Ohara, Peterson et al. 1993), diabetes (Hink, Li 
et al. 2001), atherosclerosis (White, Brock et al. 1994), and hypertension (Panza, 
Garcia et al. 1995). In diabetic mice, the aortic expression of eNOS is increased, but NO 
availability is reduced. Inhibiting eNOS reduces superoxide levels in vessels from 
diabetic mice, but increases superoxide levels in healthy mice (Hink, Li et al. 2001).  
Lower BH4 availability due to a pro-oxidant state has been described in diabetes and 
hypertension (Landmesser, Dikalov et al. 2003). Supplementation with BH4 improves 
NOS function in patients with diabetes (Heitzer, Krohn et al. 2000), chronic smokers 
(Heitzer, Brockhoff et al. 2000, Ueda, Matsuoka et al. 2000), hypertension (Hong, Hsiao 
et al. 2001), and high cholesterol (Stroes, Kastelein et al. 1997). Decreased BH4 
availability has recently been implicated as the basis for eNOS uncoupling in Fabry 
disease (Shen, Arning et al. 2017). Simply increasing eNOS expression does not 
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increase NO production because of the requirement of a proper ratio of eNOS:BH4, and 









Figure 1.3. Role of BH4 in eNOS uncoupling. Left: After calcium activates 
calmodulin (CaM), and BH4 is available, electrons from the reductase domain of 
one monomer flow to the oxygenase domain of the other monomer, via electron 
transfer from NADPH to FAD, FMN, BH4, and the ferrous-dioxygen complex 
(Fe). Reduction of molecular oxygen (O2) is coupled to L-arginine (L-Arg) 
oxidation, resulting in production of L-citrulline (L-Cit) and NO. Right: When BH4 
is not available, L-Arg and the ferrous-dioxygen complex dissociate. Electrons 
transfer to O2, and superoxide (O2
−•) is generated from the oxygenase domain.1 
 
Figure 1.4. The BH4 recycling and de novo synthetic pathways. BH4 is 
synthesized from GTP through a series of reactions involving GTP 
cyclohydrolase (GTPCH), 6-pyruvoyl-tetrahydropterin synthase (PTPS), 
sepiapterin reductase (SR) and dihydrofolate reductase (DHFR). Methotrexate 
(MTX) inhibits DHFR. Sepiapterin increases BH4 production, and also inhibits 
GTPCH. GFRP (GTP cyclohydrolase feedback regulatory protein).2 
                                            
1 Figure reproduced from: Tim S. Schmidt, and Nicholas J. Alp Clin. Sci. 2007;113:47-63 
 
2 Figure reproduced from: Mark J. Crabtree et al. J. Biol. Chem. 2009;284:28128-28136 
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Overall goal and specific aims 
Cardiovascular complications are a major cause of mortality in patients with Fabry 
disease. The long-term goal of this work is to determine the link between GLA 
deficiency and vascular dysfunction. The overall objective of this study was to establish 
an in vitro model to investigate potential mechanisms of eNOS uncoupling in the setting 
of GLA deficiency. The hypothesis was that GLA deficiency leads to a limited availability 
of a cofactor for eNOS, BH4, and that the reduction of neutral GSLs improves eNOS 
activity. 
Aim 1: Develop CRISPR/Cas9-mediated GLA-deficient EA.hy926 cell model to study 
eNOS uncoupling 
 Previously, anti-GLA siRNA treatment of EA.hy926 cells resulted in Gb3 
accumulation and eNOS uncoupling. Chapter 2 describes the process of obtaining 
CRISPR/Cas9 Gla-mutated cell lines, with a permanent absence of GLA activity. It was 
hypothesized that GLA(-) cells would have Gb3 accumulation and decreased NOS 
activity. It was found that these cells do not accumulate Gb3, but instead accumulate 
Gb4, but still have less NOS activity. In addition, it was found that the CRISPR/Cas9 
and siRNA models have elevated lyso-Gb3. Because decreased NOS activity is 
observed in both the CRISPR/Cas9 and siRNA models of GLA deficiency, we conclude 
that elevated level of lyso-Gb3, not Gb3, is a consistent marker for eNOS uncoupling in 




Aim 2: Determine if GSL accumulation, BH4 availability, and lyso-Gb3 affect eNOS 
uncoupling in GLA-deficient cells 
Chapter 3 investigates possible mechanisms of eNOS uncoupling in GLA(-) cells, with 
three main focuses: neutral GSLs, BH4 availability, and lyso-Gb3. 
First, it was hypothesized that decreasing GSLs by enzyme replacement or substrate 
reduction would improve NOS activity in GLA(-) cells. It was found that enzyme 
replacement with exogenous GLA treatment improved NOS activity, but substrate 
reduction with eliglustat treatment decreased NOS activity. These contrasting results 
suggest that it is the absence of functional GLA and not necessarily elevated globo-
series GSLs that is the cause of eNOS uncoupling. 
Second, it was hypothesized that BH4 availability is limited in GLA(-) cells, and 
increasing BH4 availability would restore NOS activity. We observed that increasing the 
availability of the NOS cofactor, BH4, did improve NOS activity in GLA(-) cells. We 
conclude that GLA deficiency leads to limited BH4 availability, which causes eNOS 
uncoupling. 
Third, it was hypothesized that GLA(-) cells secrete a substance, possibly lyso-Gb3, that 
inhibits NOS activity. However, we found that GLA(-) cells secrete a substance that 
increased NOS activity in WT cells. The increase in the observed NOS activity was not 
necessarily due to increased eNOS expression. We separately demonstrated that lyso-
Gb3 inhibits NOS activity. Therefore, we conclude that elevated lyso-Gb3 in the 
absence of GLA activity causes eNOS uncoupling, and GLA(-) cells increase NOS 
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Chapter 2: CRISPR/Cas9-mediated GLA deficient EA.hy926 cells do not 
accumulate Gb3, but still have decreased NOS activity 
Abstract 
Patients with Fabry disease, a deficiency of α-galactosidase A (GLA), have an 
increased risk of vasculopathy compared to the non-Fabry population. Past studies 
suggest that endothelial nitric oxide synthase (eNOS) dysfunction is the basis for 
impaired vascular function. In order to better study the mechanism of eNOS 
dysfunction, permanent GLA-deficient endothelial cell lines were obtained by using 
CRISPR/Cas9 gene editing to mutate Gla and eliminate GLA protein expression in 
EA.hy926 endothelial cells. Surprisingly, these cells do not accumulate 
globotriaosylceramide (Gb3), the primary substrate for GLA, but instead have elevated 
amounts of the downstream glycosphingolipid, globotetraosylceramide (Gb4). In 
contrast, EA.hy926 cells treated with siRNA against GLA have an accumulation of Gb3, 
but not Gb4. However, consistent with previous models of GLA deficiency, including the 
siRNA model, CRISPR/Cas9 GLA-deficient cells had decreased NOS activity. It was 
found that globotriaosylsphingosine (lyso-Gb3), a deacylated form of Gb3, is elevated in 
both the siRNA and CRISPR/Cas9 models of GLA deficiency in EA.hy926 cells, 
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suggesting that level of lyso-Gb3, not Gb3, is a consistent marker for eNOS uncoupling 
in Fabry disease. 
Introduction 
Fabry disease is an X-linked lysosomal storage disorder caused by mutations in the Gla 
gene. Patients experience vascular disorders, often resulting in premature death. Fabry 
disease causes elevated levels of glycosphingolipids (GSLs) with terminal α-1,4-
galactose groups due to deficient α-galactosidase A (GLA) activity. GSLs, mainly the 
globo-series GSLs, accumulate in various cells and tissues, but are especially 
prominent in endothelial cells (Linhart and Elliott 2007). Both clinical and laboratory 
studies of Fabry disease indicate the accumulation of globotriaosylceramide (Gb3), the 
substrate for GLA, in cells. However, in patients, Gb3 is not a good biomarker for 
individual symptoms (Vedder, Linthorst et al. 2007). The deacylated metabolite of Gb3, 
globotriaosylsphingosine (lyso-Gb3), better correlates with symptoms, especially in 
females with the disease (Aerts, Groener et al. 2008). Previous work suggests that the 
primary cause of endothelial dysfunction in Fabry disease is due to endothelial nitric 
oxide synthase (eNOS) uncoupling. 
One of the greatest challenges of any scientific study is choosing the appropriate model, 
especially a good in vitro model to study molecular mechanisms. Previous in vitro 
studies of Fabry disease in the Shayman group have utilized mouse aortic endothelial 
cells (MAECs) from Gla-knockout mice, and the human endothelial cell line, EA.hy926 
with GLA-siRNA knockdown (Shu and Shayman 2007, Shu, Vivekanandan-Giri et al. 
2014). Both models have provided insight into how GLA-deficiency affects GSL 
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accumulation in the cell and affects eNOS function. However, both models have 
limitations; MAECs are challenging to maintain in culture, and anti-GLA siRNA-treated 
EA.hy926 cells do not maintain the Fabry phenotype for longer than the duration of the 
siRNA treatment (3-6 days). Therefore, in this study, cell lines with a permanent 
absence of GLA protein expression were developed to be able to study eNOS 
uncoupling in the setting of GLA deficiency. These cells were obtained by using the 
CRISPR/Cas9 method of gene editing. 
The clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-
associated protein (Cas) system is found in bacteria, and is used as a method of 
protection from foreign DNA (Mojica, Ferrer et al. 1995, Jansen, Embden et al. 2002, 
Barrangou, Fremaux et al. 2007). The system uses an RNA-guided DNA nuclease to 
combat foreign nucleic acids. Specific single stranded RNA sequences recognize and 
bind to complementary sequences in foreign DNA elements, after which the Cas 
endonuclease cleaves it. The type II CRISPR-Cas system from Streptococcus 
pyogenes consists of a single Cas nuclease, Cas9, two noncoding CRISPR RNAs 
(crRNAs) – trans-activating (tracrRNA) and precursor (pre-crRNA), and has recently 
been adapted for use in human cells (Deltcheva, Chylinski et al. 2011, Jinek, Chylinski 
et al. 2012, Cho, Kim et al. 2013, Cong, Ran et al. 2013, Mali, Yang et al. 2013, Qi, 
Larson et al. 2013).  
In this study, two methods of GLA deficiency are evaluated in EA.hy926 cells. Both 
models have deficient NO production; however they have different patterns of Gb3 
accumulation. siRNA silencing of GLA leads to accumulation of Gb3, as expected. In 
contrast, CRISPR/Cas9-mediated GLA deficiency does not lead to accumulation of 
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Gb3, but instead of Gb4, another globo-series GSL (fig. 1.1). The lipid that is elevated in 
both models is lyso-Gb3, supporting other studies reporting that lyso-Gb3 is the better 
marker for Fabry disease.   
Materials and Methods 
Cell culture 
EA.hy926 cells (ATCC, Manassas, VA) were maintained at 37 °C with 95/5 O2/CO2, in 
DMEM/F-12, GlutaMAX (Thermo Fisher Scientific, Waltham, MA) supplemented with 
10% Fetal Bovine Serum (FBS), 100 U/mL penicillin, and 100 μg/mL streptomycin 
(source), which will be later referred to as “growth medium.”  
CRISPR/Cas9 plasmid generation and delivery 
In order to disrupt GLA expression in EA.hy926 cells, Single-stranded guide RNA was 
designed to target Exon 1 or Exon 2 (Table 2.1) using the Optimized Design Tool 
(crispr.mit.edu). Forward and reverse single-stranded oligonucleotides (Table 1) were 
annealed to generate a double-stranded oligonucleotide. The oligonucleotide was 
cloned into the GeneArt CRISPR nuclease vector (Thermo Fisher Scientific, Waltham, 
MA), which expresses the orange florescence protein (OFP) reporter. The vector was 
transformed into One Shot TOP10 E. coli cells (Thermo Fisher Scientific, Waltham, 
MA). Bacteria were grown on LB agar plates with ampicillin and incubated at 37 °C 
overnight. Clones were selected and grown in LB broth overnight. Plasmids were 
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purified and sequenced with the U6 forward primer to verify the presence and proper 
orientation of double-stranded oligonucleotide3. 
EA.hy926 cells were plated at 600,000 cells/well on 6 well dishes. The following day, 2 
µg of CRISPR plasmid DNA was transfected using Lipofectamine 3000 (Thermo Fisher 
Scientific, Waltham, MA), and incubated with DMEM-F12 GlutaMAX™ supplemented 
with 10% FBS for 24 hours. Cells were FACS sorted on a BD FACSAria™ II flow 
cytometer (BD Biosciences, San Jose, CA) with BD FACSDiva 8.0 software. OFP 
positive cells were collected and plated onto 150 mm dishes at low density in normal 
growth conditions. Cells were allowed to grow for several days, and then cloning 
cylinders were used to isolate individual colonies. Cells were grown in the same media 
conditions described for EA.hy926 cells. 
Surveyor nuclease assay 
Colonies were grown to confluency on 100 mm dishes and harvested for DNA 
extraction (DNeasy Blood and Tissue Kit, Qiagen, Valencia, CA). The region around the 
CRISPR-targeted region was PCR amplified with the primers listed in Table 2.2 to 
detect mutations. PCR products were run on 4% agarose gels to verify that the products 
were of the expected length. The surveyor nuclease assay (Integrated DNA 
Technologies) was performed according to the manufacturer’s instructions, with slight 
modification. This nuclease cleaves mismatched DNA (due to mutations), which can be 
visualized on an agarose gel. Two different reactions were set up per colony. The first 
reaction used only DNA from that colony; the other reaction used DNA from the colony 
and DNA from EA.hy926 cells not CRISPR/Cas9 treated. The purpose for carrying out 
                                            
3 CRISPR vector cloning and plasmid purification was performed by Robert Kelly in the Shayman group. 
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both reactions was to rule out the probability that one colony may have the same Gla 
mutation on all copies of the gene. 
The DNA was denatured and then rehybridized in the thermocycler. MgCl2, surveyor 
nuclease, and surveyor enhancer were then added to each reaction. The reaction was 
incubated at 42 °C for 60 minutes. Loading dye was added to each tube and the product 
was run on a 4% agarose gel with a size ladder. Mutant colonies were identified by 
changes in the DNA size. 
CRISPR guide RNA Sequence 5’-3’ 
Exon 1, set 1 
F: GCTAGCTGGCGAATCCCATG (GTTTT) 
R: CATGGGATTCGCCAGCTAGC (CGGTG) 
Exon 1, set 2 
F: ATTGGCAAGGACGCCTACCA (GTTTT) 
R: TGGTAGGCGTCCTTGCCAAT (CGGTG) 
Exon 2 
F: GCTAGCTGGCGAATCCCATG (GTTTT) 
R: CATGGGATTCGCCAGCTAGC (CGGTG) 
Table 2.1: Forward (F) and reverse (R) nucleotides used to guide Cas9 to 
Gla. Parentheses indicate sequence complementary to the 3’ overhang 
sequence in the CRISPR nuclease vector. Two different sets of gRNAs were 
used to target exon 1. 
 







Table 2.2: Forward (F) and reverse (R) nucleotides used to amplify the 







Colonies that were identified as having a mutation were grown to confluency on 100 mm 
dishes. Cells were harvested with 0.05% trypsin-EDTA and lysed in a buffer consisting 
of 25 mM Tris-HCl, 137 mM NaCl, 2 mM EDTA, 2 mM Na3VO4, 20 mM NaF, 1% Triton 
X-100, 10% glycerol, and protease inhibitor (P8340, Sigma). Cells were probe sonicated 
on ice and centrifuged at 10,000 x g for 10 minutes at 4 °C. Supernatants were saved 
and total cellular proteins determined with bicinchoninic acid (BCA) assay using bovine 
serum album (BSA) as a standard (Pierce BCA Protein Assay Kit, Thermo Fisher 
Scientific, Waltham, MA). Thirty μg of protein were denatured with 2-mercaptoethanol in 
Laemmli buffer, heated at 95 °C for 10 minutes, and then separated on NuPAGE 4-12% 
SDS-PAGE (Thermo Fisher Scientific). Proteins were transferred to nitrocellulose 
membranes, blocked for 1 hour with 5% nonfat dry milk-TBST (tris-buffered saline, 
tween-20), then incubated with primary antibody against GLA (1:1000 in 5% milk-TBST, 
EPR58294, (ab129173) Abcam, Cambridge MA), eNOS (1:1000 in 5% nonfat dry milk-
TBST, M221 (ab76198) Abcam), or GAPDH (1:1000 in 1% BSA-TBST, #MAB374, EMD 
Millipore, Billerica, MA) overnight at 4 °C. After washing with TBST, membranes were 
incubated with anti-mouse (for eNOS and GAPDH detection) or anti-rabbit (for GLA 
detection) secondary antibody at (1:15,000 in 1% BSA-TBST). Membranes were 
washed with TBST and incubated with enhanced chemiluminescence (Pierce ECL 
Western Blotting Substrate, Thermo Fisher Scientific). Protein bands were detected with 
film exposure. The film was scanned and protein bands quantified with ImageJ 
Software. 
                                            
4 This antibody recognizes a region in the C terminus of GLA. 
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GLA enzyme activity assay 
GLA activity was measured by modification of previously reported methods (Abe, Arend 
et al. 2000). Cells were grown to confluency in T150 flasks and harvested with 0.05% 
trypsin-EDTA. Cells were probe sonicated in buffer containing 3 mg/mL sodium 
taurocholate, 28 mM citric acid, and 44 mM Na2HPO4. The lysate was centrifuged for 30 
minutes at 20,000 x g at 4 °C and supernatant was saved. Protein concentrations were 
determined using BCA assay described above. Two μg of protein was assayed in buffer 
with final concentrations of 5 mM p-nitrophenyl α-D-galactopyranoside (PNPαGal, 
substrate for GLA), 117 mM N-acetyl-D-galactosamine (NAGA, inhibitor for α-N-
acetylgalactosaminidase, another lysosomal enzyme that hydrolyzes PNPαGal (Mayes, 
Scheerer et al. 1981)) 28 mM citric acid, 44 mM Na2HPO4, and 5 mg/mL BSA. 
Reactions were incubated at 37 °C overnight and stopped by adding an equal volume of 
200 mM Na2CO3. Absorbance was read at 400 nm on a spectrometer (Molecular 
Devices SpectraMax 250, Sunnyvale, CA). 
DNA sequencing 
DNA was extracted and PCR amplified as described earlier. PCR products were run on 
a low melting temperature 2% gel. The DNA bands were viewed under UV light and 
carefully excised. DNA was extracted from isolated gel fragments using QIAquick Gel 
Extraction Kit (Qiagen, Valencia, CA). The purified DNA fragment was cloned into the 
2.1 Topo vector (Thermo Fisher Scientific, Waltham, MA). The vector was transformed 
into One Shot TOP10 E. coli cells (Thermo Fisher Scientific). Bacteria were grown on 
LB agar plates with ampicillin and incubated at 37 °C overnight. Clones were selected 
and grown in LB broth with ampicillin overnight. Plasmids were purified (QIAprep Spin 
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Miniprep Kit, Qiagen) and submitted to the University of Michigan DNA Sequencing 
Core. Sequences were analyzed using DNAStar software (Madison, WI).  
siRNA silencing of GLA in EA.hy926 cells 
Transfection of EA.hy926 cells was performed as previously described, but with minor 
modification (Shu, Vivekanandan-Giri et al. 2014). For cells that were to be harvested 
after a single transfection, the following protocol was observed: One day before 
transfection, 0.8 x 106 cells were seeded onto 150 mm cell culture dishes with growth 
medium. At the time of transfection (Day 0), growth medium was replaced with Opti-
MEM-I (Thermo Fisher Scientific, Waltham, MA). Next, anti-GLA siRNA or scrambled-
siRNA control (scr-siRNA) was mixed with Lipofectamine RNAiMax (Thermo Fisher 
Scientific) according to the manufacturer’s protocol. After 8 hours, the medium was 
replaced with growth medium. Cells were harvested on Day 1 or 3 post-transfection. 
For cells that were to be harvested after a double transfection, the following protocol 
was observed. One day before transfection, 0.7 x 106 cells were seeded onto 150 mm 
cell culture dishes with growth medium. The same 3-day transfection protocol was 
followed as described above, but instead of harvesting the cells on Day 3, cells were 
transfected once more with the same treatment, and later harvested on Day 6. 
Lipid extraction 
Cells were grown to confluency on 150 mm cell culture dishes and harvested by 
scraping into 700 μL PBS. The cell suspension was transferred into 16 mm x 100 mm 
glass tubes, and 1 mL chloroform and 2.4 mL methanol were added. After water bath 
sonication, protein was precipitated by centrifuging at 2400 x g for 30 minutes. The 
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supernatant was transferred to a new glass tube and 4.5 mL chloroform and 1.2 mL 
0.9% NaCl were added. The sample was centrifuged at 900 x g for 5 minutes. The 
upper aqueous phase was discarded, and the lower organic phase was washed twice 
with 2 mL methanol and 0.8 mL 0.9% NaCl. The lower phase was extracted using a 1 
mL glass syringe (Hamilton, Reno, NV) and transferred to a new glass tube. Lipids were 
dried under a stream of nitrogen. 
Total phospholipid assay 
To measure the lipid content of samples, total phospholipid was determined (Ames 
1966). Dried lipids were suspended in 500 μL of chloroform/methanol (2:1, v/v). Thirty 
μL of sample was transferred to 13 x 100 mm glass tube, and 30 μL of 10% 
Mg(NO3)2.6H2O in 95% EtOH was added. The mixture was dried under a stream of 
nitrogen and ashed for 30 seconds over a flame. After cooling to room temperature, 300 
μl of 0.5 M HCl was added and incubated at room temperature for 30 minutes. Then, 
700 µL of (1:6, v/v) 10% ascorbic acid: 0.42% (NH4)2Mb·4H2O was added and samples 
and standards were incubated for 45 minutes at 45 °C. Samples were cooled to room 
temperature and absorbancy measured at 820 nm. Samples were compared to 
standards of 0, 5, 10, 20, 30, 40 µL of 1 mM KH2PO4, that were prepared 
simultaneously. Total phospholipid was calculated according to the standard curve. The 
volume according to 100 nmol of total phospholipid was transferred to a new glass tube 





Alkaline methanolysis and acid hydrolysis 
To dried lipids, 2 mL chloroform and 1 mL 0.21 M NaOH in 100% methanol were added. 
Samples were incubated at room temperature for 1 hour. The reaction was terminated 
by addition of 0.8 mL 0.25 M HCl and centrifuged at 900 x g for 5 minutes. The upper 
aqueous phase was removed and lower organic phase was transferred with a 1 mL 
Hamilton syringe to a new 16 mm x 125 mm glass tube. Four mL methanol and 1.6 mL 
0.05 M HCl/25 mM HgCl2 were added. The mixture was incubated at 37 °C for 15 
minutes. 2 mL of chloroform and 1.6 mL of water was added. Samples were centrifuged 
at 900 x g for 5 minutes. The upper aqueous phase was removed and 2 mL methanol 
and 1 mL 30 mM EDTA pH 8.0 were added to the lower organic phase. Samples were 
centrifuged and the upper phase was removed again. The lower organic phase was 
washed twice with 2 mL methanol and 1.6 mL water. The lower layer was transferred 
with a 1 mL glass syringe to a new 12 x 100 mm glass tube and dried under a stream of 
nitrogen. 
Thin layer chromatography – LacCer, Gb3, and Gb4 measurements 
One hundred nmol of total phospholipid was applied to a silica high performance TLC 
plate (Sigma-Aldrich). The plate was first developed in a solvent system consisting of 
chloroform/methanol (98:2, v/v), and air dried. The plate was then developed in a 
solvent system consisting of chloroform/methanol/acetic acid/water (61/31/5/3, v/v/v/v) 
and air dried. Plates were submerged in 8% (wt/vol) cupric sulfate pentahydrate in 
water/methanol/H3PO4 (60:32:8, v/v/v), and charred for 10 minutes at 150 °C, or were 
sprayed with 1% orcinol in 11% H2SO4 and charred at 130 °C for 5 minutes. Plates were 
scanned and densinometry measured using ImageJ software. Lipids were quantified by 
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running GlcCer, LacCer, Gb3, and Gb4 standards on each plate (Matreya LLC, State 
College, PA). 
Exogenous GLA treatment 
Cells (1.0 x 106) were seeded on 150 mm cell culture dishes with growth medium. The 
following day, growth medium was replaced with fresh media, and 3 U of α-
galactosidase A (Green coffee bean extract, Sigma), was added. Cells grew for 3 days 
and were harvested for lipid analysis with TLC. 
Eliglustat treatment 
Cells (1.0 x 106) were seeded on 150 mm cell culture dishes with DMEM/F12 GlutaMAX 
supplemented with 5% FBS. The following day, medium was replaced with DMEM/F12 
GlutaMAX supplemented with 2% FBS. Cells were treated with either PBS vehicle 
control, 20 or 200 nM eliglustat. Cells were harvested 3 days later for lipid analysis with 
TLC. 
NOS activity measurement 
Endothelial nitric oxide synthase (eNOS) activity in EA.hy926 cell lysates was analyzed 
by using a NOS activity assay kit (Cayman Chemical, Ann Arbor, MI) according to the 
manufacturer’s instructions. This assay measures the biochemical conversion of L-
arginine to L-citrulline by NOS. Cells were harvested with 0.05% trypsin-EDTA and 
washed with PBS two times. Cell pellets were lysed in the provided homogenization 
buffer (final concentration 1 mM EDTA and 1 mM EGTA in 25 mM Tris-HCl (pH 7.4) 
buffer). After brief sonication, samples were centrifuged at 12,000 x g for 5 minutes, and 
supernatants transferred to new tubes. Cell lysates (5 µL) were incubated at room 
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temperature for 3 hours with 1 µCi [3H]L-arginine (PerkinElmer), 100 nM calmodulin, 
and the provided reaction buffer (final concentration 1 mM NADPH, 600 µM CaCl2, 25 
mM Tris-HCl (pH 7.4), 3 µM tetrahydrobiopterin, 1 µM flavin adenine dinucleotide, and 1 
µM flavin adenine mononucleotide in 50 µL). The reaction was stopped by adding 400 
µL of 5 mM EDTA in 50 mM HEPES (pH 5.5) buffer.  The provided resin was added to 
each sample to remove [3H]L-arginine. Radioactivity due to [3H]L-citrulline was 
measured as counts per minute (cpm) using a scintillation counter. Cpm were also 
measured in samples with no cell lysate as a background control. NOS activity of each 
sample was calculated by subtracting background cpm from the cpm for each sample, 
and then normalizing to total protein in each 5 µL sample, determined by the BCA 
protein assay. 
Lyso-Gb3 measurement 
To measure lyso-Gb3 in EA.hy926-CRISPR/Cas9 clonal cell lines, 0.7 x 106 cells were 
seeded on 100 mm dishes. The following day, media was replaced with fresh growth 
media. Three days later, media was collected and cells harvested with 0.05% trypsin-
EDTA. Cells and media were collected the same way in siRNA-treated EA.hy926 cells 
with the transfection method described above. Cell pellets were sonicated on ice in 200-
250 μL PBS, centrifuged at 12,000 x g, and supernatant collected. BCA protein assay 
was performed. Lyso-Gb3 was measured with previously published methods5 (Gold, 
Mirzaian et al. 2013). Results were normalized to protein concentration. 
 
                                            




Data were analyzed by using Prism 7.0 software (GraphPad Software Inc, La Jolla, CA). 
Significance was determined by two-way analysis of variance (ANOVA) with Dunnett's 
or Sidak’s multiple comparisons test. Values are shown as mean ± SEM. Differences 
between groups were considered statistically significant at a P-value of <0.05. 
****P<0.0001, ***P<0.001, **P<0.01, *P<0.05. 
Results 
CRISPR/Cas9-mediated gene editing of Gla to obtain GLA-deficient EA.hy926 
cell lines 
In order to disrupt GLA expression in EA.hy926 cells, Gla-specific single-stranded guide 
RNA (gRNA) was designed to target exon 1 or 2 of Gla (table 2.1). EA.hy926 cells were 
transfected with a CRISPR/Cas9 vector that contained the exon-specific gRNA and 
orange florescence protein (OFP). These cells were FACS sorted (table 2.3), then 
grown and analyzed by surveyor mutation analysis for a mutation in the targeted 
regions (fig. 2.1). After confirming the presence of mutant cells, single cell colonies were 
grown and surveyor mutation analysis was repeated (table 2.3). The first transfection 
and FACS sorting using the exon 2-targeted gRNA did not yield GLA(-) clonal cell lines. 
Therefore, the procedure was repeated to target exon 2, and this time, GLA(-) clonal 
cell lines were obtained. CRISPR/Cas9 transfection with the exon 1, set 1 gRNA did not 
yield GLA(-) clonal cell lines. Because GLA(-) clonal cell lines were obtained with the 
other gRNA targeting exon 1, transfection with the exon 1, set 1 gRNA was not 
repeated. For studies in chapters 2 and 3, clonal cell lines from exon 1, set 2 gRNA, 
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were used. The DNA sequence of the Gla-exon 1 targeted region is shown in figure 2.2. 
Results from experiments using exon 2 gRNA clonal cell lines are included in the 
appendix. 
Colonies that have a mutation in Gla may still express GLA because there is probably 
more than one copy of the X chromosome in EA.hy926 cells (Edgell, McDonald et al. 
1983). Western blot confirmed the absence of GLA protein expression in 4 clonal cell 
lines from the exon 1 set 2 gRNA group (fig 2.4). Experiments are performed with these 
clonal cell lines, named 2, 5, 12, and 14. A single base pair deletion was detected in 
these cells (fig. 2.2). There is a possibility that clones 5, 12, and 14 originated from the 
same cell due to having the same mutation. One wild type (WT) colony that was 
negative for a mutation in the surveyor assay, clone number 17, was used as a wild 
type control in all assays. A western blot of siRNA-GLA knockdown is also shown for 
comparison (fig. 2.4). Treatment with scrambled siRNA is used as a control for the 
siRNA transfection procedure. 
Clonal cell lines were grown, harvested, and GLA activity was determined by incubated 
cell lysates with the artificial GLA substrate, PNP-α-Gal, and measuring absorbance at 
400 nm for the product, p-nitrophenol. The GLA-deficient cells 2, 5, 12, and 14 have 




Figure 2.1: Surveyor mutation analysis of CRISPR/Cas9 gRNA targeting 
exon 1 or 2 of Gla. 
 
 E1-1 E1-2 E2 (first) E2 (second) 
# OFP cells 2106 1160 2028+2414 5732+2668 
# Isolated 
colonies 
20 19 28 17 
# Surveyor 
mutants 
4 14 0 - 
# No GLA 
expression 
0 4 0 4 
Table 2.3: Results of CRISPR/Cas9 transfection with gRNAs targeting 
exons 1 and 2 of Gla. FACS sorted cell count, and number of colonies indicating 
a mutation in the Surveyor assay, and the number of colonies with no GLA 
expression on Western blot. 
 
 
Figure 2.2: Sequence of the region of Gla – Exon 1 that was targeted by 
CRISPR/Cas9. The target sequence is indicated by the red box, which is the 
sequence complementary to the gRNA used in the CRISPR/Cas9 transfection. 
CRISPR/Cas9 caused single base pair deletions resulting in frameshift 




Figure 2.3: GLA Enzyme Assay
activity assay. Pnp-α-gal is an artificial substrate for GLA that 
nitrophenol. The resulting color change can be measured by reading the 
absorbance at 400 nm by
lines 2, 5, 12, and 14, exhibit background GLA activity in comparison to 
n=3 
 
Figure 2.4: CRISPR/Cas9 gene editing or anti
eliminates GLA expression
denatured, separated on a 4
and blotted for GLA and GAPDH. 
14 do not express GLA. Clone 17 represents
CRISPR/Cas9-model studies. 
eliminates GLA expression. Scrambled (scr) siRNA controls express GLA.
52 
  
. Left: Reaction scheme of the GLA enzyme 
is converted to p
 spectrophotometry.  Right: Cell lysates from clonal cell 
 
-GLA siRNA treatment 
 in EA.hy926 cells. Thirty μg of protein was
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CRISPR/Cas9 GLA-deficient cells have a different lipid profile compared to 
siRNA-mediated GLA-knockdown cells 
Previously published results showed that siRNA silencing of GLA in EA.hy926 cells for 3 
or 6 days results in Gb3 accumulation (Shu, Vivekanandan-Giri et al. 2014). The siRNA 
assay was repeated, and cells harvested for lipid extraction. CRISPR/Cas9 GLA-
deficient cell lines were also grown and harvested for lipid extraction. Total phospholipid 
assay was performed to determine lipid content of samples, and 100 nmol of total 
phospholipid was subjected to alkaline methanolysis and acid hydrolysis. The amount of 
globo-series GSLs was determined by TLC with cupric sulfate charring (example shown 
in fig. 2.7). LacCer and Gb3 were quantified. In agreement with previously reported 
results (Shu, Vivekanandan-Giri et al. 2014), treating EA.hy926 cells with anti-GLA 
siRNA for 6 days increased Gb3 content two-fold over treatment with scr-siRNA control 
(fig 2.5). However, CRISPR/Cas9 GLA(-) cells did not have an increase in Gb3 content 
compared with WT controls (fig 2.6), and in fact had a slight decrease. Furthermore, 
while anti-GLA siRNA treatment increased LacCer content, the CRISPR/GLA –deficient 
cells all have decreased LacCer content. In summary, although both the siRNA 
silencing and CRISPR/Cas9 methods eliminate GLA expression (fig 2.4) in EA.hy926 





Figure 2.5: siRNA-GLA knockdown increases LacCer and Gb3. 
EA.hy926 cells were treated with scrambled siRNA (scr-siRNA) control or anti-
GLA siRNA for up to 6 days. Lipids were extracted for TLC analysis. TLC plates 
were charred with 8% (wt/vol) cupric sulfate pentahydrate in 
water/methanol/H3PO4 (60:32:8, v/v/v). There is a time-dependent accumulation 





Figure 2.6: CRISPR/Cas9-gene edited GLA(-) cells do not accumulate 
LacCer or Gb3. GLA(-) clonal cell lines were grown to confluency, and lipids 
were extracted for TLC analysis. TLC plates were charred with 8% (wt/vol) cupric 
sulfate pentahydrate in water/methanol/H3PO4 (60:32:8, v/v/v). GLA-deficient 
cells do not have more Gb3 than the WT control. Clone 2 has less Gb3 than WT. 
All GLA-deficient Clonal cells have less LacCer than WT. n=4-12 ****p<0.0001, 









GLA deficient cells accumulate Gb4 
In light of these surprising results, we hypothesized that other neutral GSLs may be 
accumulating in response to deficient GLA activity. In addition, we observed that the 
band at the bottom of the TLC plate exhibited noticeable differences between WT and 
GLA(-) samples. Specifically, the GLA(-) samples had a band with a higher Rf value that 
was very faint or absent in samples from clone 17 (WT) cells (fig. 2.7, top). Based on 
this mobility, we hypothesized that this band may represent the downstream globo 
series GSL, globotetraosylceramide (Gb4). Because of similar properties to 
sphingomyelin, with respect to polarity, Gb4 cannot be clearly separated on the TLC 
plate in order to quantify it. Therefore, instead of charring the TLC plate with cupric 
sulfate solution, the TLC plate was stained with 1% orcinol (w/v) solution in 11% H2SO4 
(v/v) to detect only carbohydrate moieties. This staining solution was used for the 
remaining studies to measure levels of neutral GSLs in cell lysates. Representative TLC 
plates with both staining methods are shown in figure 2.7. 
Cell lysates from GLA-deficient cells have a 2.5 to 4 fold higher amount of Gb4 content 
over the WT cell line (fig. 2.9). siRNA-GLA knockdown also increases Gb4, but not to 





Figure 2.7: Neutral GSLs are analyzed by TLC. Top: A representative TLC 
plate charred with 8% (wt/vol) cupric sulfate pentahydrate in 
water/methanol/H3PO4 (60:32:8, v/v/v) is shown. GLA-deficient cells exhibit 
changes in lipids near the bottom of the plate, which is most likely to be Gb4. 
Bottom: A representative TLC plate charred with 1% (wt/vol) orcinol in 11% (v/v) 






Figure 2.8: GLA knockdown causes lipid accumulation. EA.hy926 cells were 
treated with scrambled siRNA (scr-siRNA) control or anti-GLA siRNA for up to 6 
days. Lipids were extracted for TLC analysis. TLC plates were charred with 1% 
(wt/vol) orcinol in 11% (v/v) H2SO4. There is a time-dependent accumulation of 
LacCer, Gb3, and Gb4. n=10 ***p<0.001, **p<0.01, when compared to scr-siRNA 
control (100%, dotted line). 
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Figure 2.9: GLA(-) cells (CRISPR/Cas9 gene edited) accumulate Gb4 
CRISPR/Cas9 clonal cell lines were grown to confluency, and lipids were 
extracted for TLC analysis. TLC plates were charred with 1% (wt/vol) orcinol in 
11% (v/v) H2SO4 for detection of carbohydrate groups. All GLA-deficient clonal 
cells have more Gb4 than WT (100%, dotted line). n=10 ****P<0.0001, 













Exogenous GLA and eliglustat treatments decrease neutral GSLs 
Previously, it was shown that two different pharmacological methods, treatment with 
recombinant GLA (enzyme replacement) or an inhibitor of glucosylceramide synthase 
(substrate deprivation), can lower Gb3 content (Shu, Murphy et al. 2005, Shu and 
Shayman 2007). Although Gb3 is not increased in the CRISPR/Cas9 GLA-deficient 
cells, it remained to be determined whether Gb4 content is affected by these 
treatments. Cells were treated with exogenous GLA (3 U) or eliglustat (20 or 200 nM) in 
cell culture media for 3 days. Lipids were extracted and analyzed by TLC and GSLs 
were visualized by charring with orcinol-sulfate solution. Both treatment methods 
decreased levels of LacCer and Gb3 in all cells. Gb4 was only lowered in GLA-deficient 
cells. GLA treatment resulted in comparable levels of LacCer and Gb3 in GLA-deficient 
and WT cells, but not Gb4 (fig. 2.10). In contrast, 20 nM eliglustat treatment did not 
affect Gb3 levels compared to the vehicle control for each cell line, but decreased 
LacCer and Gb4. The 200 nM treatment more severely reduced Gb4 content in GLA-








Figure 2.10: Treatment with GLA decreases globo-series GSLs. 
CRISPR/Cas9 clonal cell lines were treated with exogenous α-galactosidase A 
(empty bars) or vehicle (shaded bars) for 3 days and lipids were extracted for 
TLC analysis. TLC plates were charred with 1% (wt/vol) orcinol in 11% (v/v) 
H2SO4 for detection of carbohydrate groups. Dotted line represents 100% of WT 
control treatment. Values presented as % of WT control (dark gray bars). 







































































































Figure 2.11: Treatment with eliglustat decreases globo series GSLs. 
LacCer, Gb3, and Gb4 content of cells treated with vehicle, 20 nM, or 200 nM 
eliglustat for 3 days. Values presented as %WT - vehicle (empty bars). Dotted 
line represents 100% of WT control treatment. Significance is indicated in 
comparison to 17(WT) of each treatment. n=3 ****P<0.0001, ***P<0.001, 
**P<0.01, *P<0.05. 


























































Specificity of exogenous GLA for Gb3 catabolism 
To confirm the specificity of GLA for Gb3, extracted lipids (100 nmol of total lipid 
phosphate) were incubated with GLA overnight at 37 °C. The reaction was stopped, and 
samples were washed to obtain neutral GSLs and developed by TLC. The most 
prominent changes are seen with Gb3 content. A representative TLC plate is shown 
(fig. 2.12) to exhibit how the reaction mixture contaminates the samples with substances 
that run alongside LacCer, but do not interfere with Gb3 measurement. GLA digest 
specifically decreases Gb3 content in lipid samples (fig. 2.13). These results also 






Figure 2.12: GLA specifically degrades Gb3 
Cells were grown to confluency and lipids extracted. 100 nmol aliquots of lipids 
were incubated overnight with either α-galactosidase A (GLA) or vehicle control 
(V), and developed on a TLC plate, then charred with 1% (wt/vol) orcinol in 11% 
(v/v) H2SO4. Reagents in the reaction mixture do not interfere with quantification 






Figure 2.13: Incubation of extracted lipids with GLA decreases Gb3 
content. Cells were grown to confluency and lipids extracted. 100 nmol aliquots 
of lipids were incubated overnight with either α-galactosidase A (GLA, empty 
bars) or vehicle control (shaded bars), and developed on a TLC plate, then 
charred with 1% (wt/vol) orcinol in 11% (v/v) H2SO4. GLA treatment specifically 
decreases Gb3 content in lipid samples. Dotted line indicates 100% clone 




































































































Elevated lyso-Gb3 in GLA-siRNA knockdown and CRISPR/Cas9 GLA(-) cells 
EA.hy926 cells were treated with siRNA against GLA or with scr-siRNA control for 3 or 6 
days, or CRISPR/Cas9 Gla-edited cells were grown to confluency on 100 mm dishes. 
All cells were harvested and sonicated in PBS, and lyso-Gb3 was measured with UPLC-
MS6 (Gold, Mirzaian et al. 2013). Cell lysates from CRISPR/Cas9 GLA(-) clonal cell 
lines had a 3 to 4-fold increase of lyso-Gb3 compared to WT control (fig. 2.14). 
Similarly, 6-day treatment of anti-GLA siRNA in EA.hy926 cells caused a significant 
increase of lyso-Gb3 compared to scr-siRNA control and 3-day anti-GLA siRNA treated 
cells. In contrast with LacCer, Gb3, and Gb4 measurements between the siRNA and 
CRISPR/Cas9 models of GLA-deficiency, lyso-Gb3 is a marker that is common between 
the two models. This corroborates clinical studies reporting that lyso-Gb3 is a more 
reliable marker for Fabry disease than is Gb3 (Vedder, Linthorst et al. 2007, Smid, van 
der Tol et al. 2015).  
 
 
                                            





Figure 2.14: Elevated lyso-Gb3 in GLA deficient cell lysates. 
Lyso-Gb3 is elevated in 6-day anti-GLA siRNA treated cells compared to 3-day 
anti-GLA siRNA treatment and 6-day scrambled-siRNA (scr) treatment. Lyso-
Gb3 is elevated in CRISPR/Cas9 GLA-deficient cells compared to clone 17 (WT). 
n=3. ****P<0.0001, ***P<0.001, **P<0.01. 
 
Decreased NO production and eNOS expression in GLA deficient cells 
The CRISPR/Cas9-EA.hy926 GLA deficient cell model is the only in vitro model that we 
are aware of that has been reported to not have a consistent increase in Gb3 content. 
However, consistent with previous models of GLA deficiency, GLA-deficient cells had 
decreased NO production (fig. 2.15). Three of the four GLA(-) cell lines had 40-50% of 





























of NOS activity compared to WT. To verify [3H]L-citrulline that was measured in the 
NOS activity assay originated from NOS activity, reactions were repeated with the 
addition of a competitive NOS inhibitor, NG-nitro-L-arginine (L-NNA) to the NOS reaction 
mixture. There was no detectable [3H]L-citrulline above background with L-NNA (data 
not shown).  
A possible reason for decreased NOS activity is reduced eNOS expression. A Western 
blot was performed to detect eNOS expression in WT and GLA deficient cells (fig. 2.16). 
Although there is a trend of decreased eNOS expression in GLA-deficient cells that 
correlates with decreased NOS activity, the change was not statistically significant 
(p=0.08 for clone 12 compared with 17(WT)). 
 
Figure 2.15: GLA(-) cells have less NOS activity. NOS activity was measured 
in cell lysates from clonal cell lines. NO production was significantly lower in 
GLA(-) cell lines, 5, 12, and 14, when compared to the WT control 17. n=18 






Figure 2.16. GLA(-) cells have less eNOS protein expression.
Thirty μg of protein was separated on 4
nitrocellulose membranes, and blotted for eNOS and GAPDH. 
representative Western b
WT control. Bottom: Quantification of W
decrease in eNOS expression
(p=0.08). Clone 2, n=3; clones 5, 12, and 14, n=4; clone 17(WT), n=6.
 
Discussion  
In the United States, the only therapeutic to treat the underlying cause
is enzyme replacement therapy (ERT) with recombinant GLA 
2001, Eng, Guffon et al. 2001)
has been shown to clear Gb3 from kidney cells 
reduce renal, cardiac, and CNS events 
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 in clone 12, but is not statistically significant 
 
 of Fabry disease
(Eng, Banikazemi et al. 
. Based on clinical trials, ERT is the standard of care as it 
(Thurberg, Rennke et al. 2002)
(Banikazemi, Bultas et al. 2007). However
 clinical manifestations of Fabry disease, including 








cardiovascular outcomes (Hopkin, Cabrera et al. 2016). The following are a few reasons 
why the benefit of ERT may be limited. First, infusions are administered on a weekly or 
bi-weekly basis, which may be insufficient for Fabry patients to have normal, consistent, 
GLA activity (Schiffmann, Askari et al. 2007). Second, patients may develop an immune 
reaction to the infused enzyme, which can decrease the efficacy (Linthorst, Hollak et al. 
2004, Rombach, Aerts et al. 2012). Third, when ERT is started after there has been 
organ damage, ERT does not halt disease progression (Cabrera, Politei et al. 2017). 
Considering the high cost of ERT ($200,000 per year for life), there is a need for a good 
biomarker of Fabry disease. A biomarker would be useful for predicting who may benefit 
from ERT or if ERT is effective for a particular Fabry patient. Although Gb3 is the 
primary substrate of GLA, no strict correlation exists between plasma Gb3 levels and 
clinical manifestations of Fabry disease. In hemizygotes, Gb3 accumulation begins in 
utero, before clinical symptoms, whereas heterozygotes may have normal Gb3 levels 
with or without clinical symptoms. In addition, Gb3 is not a good biomarker for 
monitoring the efficacy of ERT unless Gb3 is elevated prior to initiation of treatment 
(Young, Mills et al. 2005, Vedder, Strijland et al. 2006, Vedder, Linthorst et al. 2007). 
Lyso-Gb3, a deacylated form of Gb3, has emerged as a biomarker for Fabry disease 
(Aerts, Groener et al. 2008). Lyso-Gb3 is elevated in plasma from Fabry patients and in 
GLA-deficient mice. The level of lyso-Gb3 in plasma decreases after initiation of ERT. 
Furthermore, lyso-Gb3 is useful for monitoring Fabry disease in females. Heterozygous 
females have normal circulating levels of GLA and Gb3, but may still experience 
symptoms of the disease. Symptomatic heterozygous females have elevated plasma 
lyso-Gb3, while lyso-Gb3 cannot be detected in asymptomatic heterozygous females 
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(Aerts, Groener et al. 2008, Rombach, Dekker et al. 2010, Togawa, Kodama et al. 2010, 
Smid, van der Tol et al. 2015). 
Lyso-lipids found to be elevated in other lipid storage diseases, for example, Krabbe 
disease (galactocerebroside), and Gaucher disease (glucosylsphingosine), have been 
shown to have toxic effects (Tanaka and Webster 1993, Schueler, Kolter et al. 2003). 
Lyso-Gb3 has also been shown to be involved in the pathogenesis of Fabry disease. 
Lyso-Gb3, but not Gb3 or lactosylsphingosine, promotes smooth muscle cell 
proliferation, which may contribute to the increased intima-media thickening seen in 
patients (Aerts, Groener et al. 2008). Lyso-Gb3 induces podocyte injury, which is an 
early feature of Fabry nephropathy (Sanchez-Nino, Sanz et al. 2011). 
In this study, we have shown that contrary to other in vitro models of Fabry disease, 
CRISPR/Cas9 – induced GLA(-) cells do not accumulate Gb3 (figs. 2.6 and 2.9), the 
primary substrate for GLA.  However, there is consistency with other models and data 
from Fabry patients regarding elevated lyso-Gb3 (Aerts, Groener et al. 2008, Gold, 
Mirzaian et al. 2013, Smid, van der Tol et al. 2015). GLA(-) EA.hy926 cells, either 
CRISPR/Cas9 or siRNA – mediated, exhibit an increase of lyso-Gb3 (fig. 2.14). 
Experiments in chapter 3 will address the direct effect of lyso-Gb3 on eNOS uncoupling. 
We chose the CRISPR/Cas9 method of gene editing to obtain permanent cell lines that 
are GLA deficient. Previously, the Shayman group used primary cells isolated from 
mouse aortas of Gla knockout mice (mouse aortic endothelial cells, MAECs), which 
were useful for characterizing lipid changes and effectiveness of GlcCer synthase 
inhibition for decreasing accumulating Gb3 (Shu, Murphy et al. 2005). However, this 
model was not sustainable for studying long-term consequences of treating cells with 
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different agents since these cells could only be maintained in cell culture for a limited 
time (3 to 6 days). The anti-GLA siRNA EA.hy926 cell model was useful for making 
initial observations of how GLA-deficiency affects NOS activity, even when GLA was 
absent for only a few days, and for identifying 3-nitrotyrosine (a marker of eNOS 
uncoupling (Heinecke 2002)) as a biomarker for GLA deficiency (Shu, Vivekanandan-
Giri et al. 2014). However, similar to MAECs, this in vitro model is not sustainable 
because a single siRNA treatment lasts for only 3 days. There can also be off-target 
effects of the siRNA. 
One advantage of the CRISPR/Cas9 GLA(-) cell model is that they can be continually 
passaged and retain the GLA(-) characteristic with no additional treatment. To account 
for off-target effects of the initial CRISPR/Cas9 transfection, multiple single cell colonies 
were isolated, grown, and analyzed. In this study, lyso-Gb3 is the most consistent 
marker of GLA deficiency. While there was variability of measurement of Gb3, Gb4, and 
NOS activity (figs. 2.6, 2.9, and 2.15), the lyso-Gb3 levels were consistently elevated in 
all four GLA(-) clonal cell lines (fig. 2.14). GLA(-) clonal cell lines isolated from treatment 
with a CRISPR/Cas9 vector targeting exon 2 of Gla also have variability in the lipid 
measurements (figs. A.3, A.4) and NOS activity (fig A.5). 
As described above, ERT with recombinant GLA is currently the only approved 
treatment for Fabry disease in the United States. Substrate deprivation is an alternative 
approach to reducing accumulation of globo-series GSLs; using a small molecule 
inhibitor of glucosylceramide (GlcCer) synthase prevents the de novo synthesis of 
downstream GSLs, including LacCer, Gb3, and Gb4 (Abe, Arend et al. 2000, Abe, 
Gregory et al. 2000). Experiments performed in an in vitro model of Fabry disease using 
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recombinant GLA and GlcCer synthase inhibitors have indicated that both 
pharmacological methods can reduce the accumulation of Gb3 in GLA-deficient cells 
(Shu, Murphy et al. 2005). Similarly, in our study, treating GLA(-) EA.hy926 cells with 
exogenous GLA or the GlcCer inhibitor, eliglustat, decreases the accumulation of globo-
series GSLs (figs 2.10 and 2.11). 
A hypothesis for the vasculopathy of Fabry disease is that GLA deficiency causes 
changes to the plasma membrane. A previous study of mouse aortic endothelial cells 
reported that although GLA is a lysosomal enzyme, the primary substrate, Gb3, 
accumulates in the lysosome and in the plasma membrane (Shu and Shayman 2007). 
In the present study, accumulation of GSLs was not examined in the caveolar 
membrane, however it is possible that Gb3 (or Gb4) is accumulating at the plasma 
membrane but total cell Gb3 is unchanged. The plasma membrane is the site of eNOS 
activity. eNOS uncoupling is characterized by the production of superoxide instead of 
nitric oxide (NO), and occurs when electrons from NADPH in the reductase domain of 
eNOS flow to molecular oxygen rather than to the oxygenase domain to reduce L-
arginine to L-citrulline with the NO byproduct (fig. 1.3). The reduction of molecular 
oxygen forms superoxide (Vasquez-Vivar, Kalyanaraman et al. 1998, Xia, Tsai et al. 
1998), which reacts with NO to produce peroxynitrite (ONOO-). ONOO- is a reactive 
nitrogen species that can oxidize the eNOS cofactor, tetrahydrobiopterin (BH4) to the 
inactive form, dihydrobiopterin (BH2) (Milstien and Katusic 1999). 
A biomarker for the presence of ONOO-, 3-nitrotyrosine, is derived from protein 
nitrosylation (Heinecke 2002). A previous study of Fabry disease showed that 3-
nitrotyrosine is elevated in the siRNA-EA.hy926 GLA(-) and Gla-knockout mouse 
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models, as well as in plasma from Fabry patients (Shu, Vivekanandan-Giri et al. 2014). 
In the current study, NOS activity was shown to be decreased in GLA(-) cells. There is a 
decrease in eNOS protein expression, but the difference did not reach statistical 
significance (fig. 2.15). Although 3-nitrotyrosine was not measured in this study, to 
determine if GLA(-) cells had increased oxidative stress, total glutathione was 
measured, and found to be decreased compared to WT, indicating the cells had 
increased oxidative stress (fig A.1). A recent study (Shen, Arning et al. 2017) observed 
a decrease of BH4 in the heart and kidney of Fabry mice, and an inverse correlation 
between Gb3 and BH4 levels in tissues. Glutathione levels in Fabry mouse tissues were 
also found to be decreased compared to WT. BH4 availability in our CRISPR/Cas9 
GLA(-) cells will be addressed in chapter 3. 
eNOS uncoupling is a characteristic of common vascular diseases that arise from a 
variety of genetic or environmental factors, like hypercholesterolemia (Ohara, Peterson 
et al. 1993), diabetes (Hink, Li et al. 2001), atherosclerosis (White, Brock et al. 1994), 
and hypertension (Panza, Garcia et al. 1995). Assessing the cause of eNOS uncoupling 
in a rare, monogenic disorder provides a window of opportunity to uncover novel 
mechanisms of eNOS regulation that would not be possible in a disease model with 
multiple variables. 
In summary, GLA-deficient EA.hy926 cells were obtained using CRISPR/Cas9 gene 
editing. Although these cells do not accumulate the primary substrate of GLA, Gb3, they 
exhibit decreased NOS activity, and have elevated lyso-Gb3. Lyso-Gb3 is better than 
Gb3 for correlating GLA deficiency with eNOS uncoupling. The CRISPR/Cas9 GLA(-) 
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Chapter 3: Mechanisms of eNOS uncoupling in GLA-deficient cells 
Abstract 
Fabry disease arises from mutations in Gla, resulting in deficiency of the lysosomal 
hydrolase, α-galactosidase A (GLA). A prominent feature of Fabry disease is vascular 
dysfunction. One of the effects of GLA deficiency is endothelial nitric oxide synthase 
(eNOS) uncoupling, where eNOS produces superoxide instead of the important 
messenger, nitric oxide (NO). In the previous chapter, CRISPR/Cas9 gene editing was 
used to eliminate GLA expression in EA.hy926 endothelial cells as a model to 
investigate the link between GLA deficiency and eNOS uncoupling in Fabry disease.  
Experiments performed in this chapter used two different methods of reducing neutral 
glycosphingolipid content to indicate that GLA function, and not necessarily elevated 
GSLs, leads to eNOS uncoupling in Fabry disease. It is also reported that eNOS activity 
was improved by increasing the availability of tetrahydrobiopterin (BH4), an important 
cofactor of eNOS. Furthermore, globotriaosylsphingosine (lyso-Gb3), which is elevated 
in GLA-deficient cells, inhibited NOS activity in cell lysates. 
Introduction 
Fabry disease is caused by deficiency of the lysosomal hydrolase, α-galactosidase A 
(GLA). The primary substrate for GLA is the globo-series glycosphingolipid (GSL), 
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globotriaosylceramide (Gb3). Loss of GLA function results in accumulation of neutral 
GSLs in various cells and tissues (Brady, Gal et al. 1967). This is a rare, X-linked, 
disease, but is often not diagnosed until later in life due to symptoms being attributed to 
other causes (Eng, Fletcher et al. 2007). 
Complications of the disease include kidney failure, neuropathy, and cardiovascular 
disease. Cardiovascular events, like myocardial infarction and stroke, are often the 
cause of premature death in Fabry patients. The only approved therapy for Fabry 
disease is enzyme replacement therapy (ERT). ERT has been shown to clear Gb3 from 
various cells and tissues. However, unless ERT is initiated early in life, before any major 
cardiovascular event, it does not prevent the occurrence of cardiovascular events 
(Hopkin, Cabrera et al. 2016). 
An alternative approach to reducing accumulation of globo-series GSLs is substrate 
deprivation, where a small molecule is used to inhibit GlcCer, which prevents the de 
novo synthesis of the downstream GSLs, including Gb3. Eliglustat tartrate (Cerdelga®, 
Genzyme) has been approved for clinical use to treat Gaucher disease, another 
lysosomal storage disease. However, proof-of-concept studies for these inhibitors were 
performed in the mouse model for Fabry disease (Abe, Arend et al. 2000, Abe, Gregory 
et al. 2000). Experiments performed in an in vitro model of Fabry disease using 
recombinant GLA and GlcCer synthase inhibitors have indicated that both 
pharmacological methods can reduce the accumulation of Gb3 in GLA-deficient cells 
(Shu, Murphy et al. 2005). 
Several experimental models of Fabry disease have suggested that endothelial nitric 
oxide synthase (eNOS) dysfunction is the basis for vasculopathy that occurs in many 
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patients with Fabry disease (Eitzman, Bodary et al. 2003, Bodary, Shen et al. 2005, 
Park, Whitesall et al. 2008, Shu, Park et al. 2009, Shu, Vivekanandan-Giri et al. 2014). 
eNOS uncoupling occurs when there is improper flow of electrons from the reductase 
domain of eNOS, to the oxidase domain. Normally, NADPH-derived electrons are 
transferred from the reductase to the oxygenase domain to oxidize L-arginine to NO and 
L-citrulline. In the case of eNOS uncoupling, however, the electrons are not transferred 
to L-arginine and are instead transferred to O2, forming O2
- instead of NO (Vasquez-
Vivar, Kalyanaraman et al. 1998, Xia, Tsai et al. 1998). O2
- can then react with NO to 
produce a reactive nitrogen species, peroxynitrite (ONOO-). ONOO- can then rapidly 
oxidize tetrahydrobiopterin (BH4) to the inactive form, dihydrobiopterin (BH2), which 
causes further uncoupling (Milstien and Katusic 1999). A biomarker for ONOO- is 3-
nitrotyrosine, which results from protein nitrosylation (Heinecke 2002).  
eNOS dysfunction has been extensively studied in more common diseases that have a 
cardiovascular dysfunction component. In diabetic mice, aortic expression of eNOS is 
increased, but NO availability is reduced. Inhibiting eNOS reduces superoxide levels in 
vessels from diabetic mice, but in healthy mice, increases superoxide levels (Hink, Li et 
al. 2001). The major cause of eNOS uncoupling in diseases with cardiovascular risk 
factors is BH4 deficiency due to increased oxidant stress. Therefore, methods to 
prevent eNOS uncoupling often target the pathways that regenerate BH4 (Li and 
Forstermann 2014). 
BH4 was discovered to be important for the NOS reaction by Stuehr and colleagues 
(Kwon, Nathan et al. 1989), and Tayeh and Marletta (Tayeh and Marletta 1989). BH4 is 
a key intermediate in the electron transfer between the reductase and oxygenase 
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domains of eNOS. BH4 was first found to stabilize the neuronal NOS (nNOS) 
homodimer (Klatt, Schmidt et al. 1995), and later the eNOS homodimer (Rodriguez-
Crespo, Gerber et al. 1996). 
BH4 is generated by two pathways (schematic fig 1.4). The de novo pathway converts 
GTP to BH4 via two intermediates. The rate-limiting step is GTP cyclohydrolase I 
(GTPCH), which catalyzes the first step in this pathway. GTPCH is regulated at the 
transcriptional and post-transcriptional levels. Sepiapterin inhibits GTPCH (Gross and 
Levi 1992) and is a substrate for the salvage pathway. 
The salvage pathway regenerates BH4 from the oxidized form, BH2. Sepiapterin 
reductase produces BH2 from sepiapterin. Then dihydrofolate reductase (DHFR) 
reduces BH2 to BH4 (Nichol, Lee et al. 1983). An increase of superoxide in endothelial 
cells causes a down-regulation of DHFR expression and BH4 levels, resulting in 
uncoupling of eNOS, which further generates superoxide. Increasing DHFR expression 
restores eNOS coupling (Chalupsky and Cai 2005). Methotrexate inhibits DHFR activity 
BH4 availability is reduced when it is oxidized, which happens in the presence of 
peroxynitrite. Peroxynitrite is formed by the reaction of superoxide and NO. Low levels 
of peroxynitrite can oxidize physiologically relevant levels of BH4 (Milstien and Katusic 
1999); impaired vasorelaxation in aortic rings from apoE-/- mice can be overcome by 
treatment with the peroxynitrite scavenger, uric acid (Laursen, Somers et al. 2001). 
In the following study, decreased NOS activity in GLA-deficient cells is improved by 
treating cells with exogenous GLA or with sepiapterin. In contrast, NOS activity is 
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reduced when treating with eliglustat or methotrexate. Lyso-Gb3 is also found to inhibit 
NOS activity. 
Materials and Methods 
Cell culture 
EA.hy926 cells (ATCC, Manassas, VA) were maintained at 37 °C with 95/5 O2/CO2, in 
DMEM/F-12, GlutaMAX (Thermo Fisher Scientific, Waltham, MA) supplemented with 
10% Fetal Bovine Serum (FBS), 100 U/mL penicillin, and 100 μg/mL streptomycin 
(source), which will be later referred to as “growth medium.” CRISPR/Cas9 gene editing 
was used to create 4 clonal cell lines (2, 5, 12, 14), originating from single cell colonies, 
and that do not express GLA (described in detail in Chapter 2). One clone (17) does not 
have a mutation in Gla, expresses GLA, and is used as the wild type (WT) control in 
these studies. 
NOS activity 
A commercially available NOS assay kit (Cayman Chemical, Ann Arbor, MI) was used 
according to the manufacturer’s instructions. This assay measures the biochemical 
conversion of L-arginine to L-citrulline by NOS. Harvested cell pellets were briefly 
sonicated on ice, centrifuged at 12,000 x g for 5 minutes, and supernatants transferred 
to new tubes. Cell lysates were incubated at room temperature for 3 hours with 1 µCi 
[3H]L-arginine (PerkinElmer), 100 nM calmodulin, and the provided reaction buffer (final 
concentration 1 mM NADPH, 600 µM CaCl2, 25 mM Tris-HCl (pH 7.4), 3 µM 
tetrahydrobiopterin, 1 µM flavin adenine dinucleotide, and 1 µM flavin adenine 
mononucleotide). The reaction was stopped by adding 5 mM EDTA in 50 mM HEPES 
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(pH 5.5) buffer.  The provided resin was added to each sample to remove [3H]L-
arginine. Radioactivity due to [3H]L-citrulline was measured as counts per minute (cpm) 
using a scintillation counter. Cpm was also measured in samples with no cell lysate as a 
background control. NOS activity of each sample was calculated by subtracting 
background cpm from the cpm for each sample, and then normalizing to total protein in 
each 5 µL sample, determined by the BCA protein assay. For assays with lyso-Gb3, 
Gb3, or glucosylsphingosine (Matreya), the reaction was carried out with the indicated 
lipid. 5 μL of cell lysate was incubated with the lipid on ice for 1 hour before adding the 
NOS assay reaction mixture, or the lipid was added to the reaction mixture and then 
added to the cell lysate. 
Exogenous GLA treatment 
Cells (1 x 106) were seeded on 150 mm cell culture dishes with growth medium. The 
following day, growth medium was replaced with fresh media, and 3 U of α-
galactosidase A (Green coffee bean extract, Sigma), was added. Cells grew for 3 days 
and were harvested for eNOS activity measurement or lipid analysis with TLC. 
Eliglustat treatment 
Cells (1 x 106)  were seeded on 150 mm cell culture dishes with DMEM/F12 GlutaMAX 
supplemented with 5% FBS. The following day, medium was replaced with DMEM/F12 
GlutaMAX supplemented with 2% FBS. Cells were treated with either PBS vehicle 





Methotrexate and sepiapterin treatment 
Cells were seeded on 100 mm cell culture dishes (1 x 106). The following day, growth 
medium was replaced with fresh growth medium, and cells were treated with either 
methotrexate (Cayman Chemical, Ann Arbor, MI), or sepiapterin (Sigma). After 18 
hours, cells were harvested for NOS activity measurement as described above. 
Conditioned media assay 
On Day 1, clonal cell lines 12 (GLA-deficient) and 17 (GLA-WT) were seeded on T75 
flasks (1 x 106 cells), “donor cells,” with growth media. On day 2, the media was 
replaced with fresh growth media. In a separate set of flasks with no cells, growth media 
was added as a control (“cell-free media”). On Day 4, 1 x 106 cells were seeded on T75 
flasks, “recipient cells,” with growth media. On Day 5, media was removed from “donor 
cells,” centrifuged to remove debris, and used to replace the media on “recipient cells.” 
Donor cells were harvested with 0.05% trypsin-EDTA, washed with PBS, and frozen at -
80 °C. On Day 8, “recipient cells” were harvested the same way. eNOS activity was 
assayed in lysates from donor and recipient cells as described earlier. Lysates were 
also used for Western blot analysis of eNOS expression. 
Western blotting 
Cells were harvested with 0.05% trypsin-EDTA and lysed in a buffer consisting of 25 
mM Tris-HCl, 137 mM NaCl, 2 mM EDTA, 2 mM Na3VO4, 20 mM NaF, 1% Triton X-100, 
10% glycerol, and protease inhibitor (P8340, Sigma). Cells were probe sonicated on ice 
and centrifuged at 10,000 x g for 10 minutes at 4 °C. Supernatants were saved and total 
cellular proteins determined with bicinchoninic acid (BCA) assay using bovine serum 
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album (BSA) as a standard (Pierce BCA Protein Assay Kit, Thermo Fisher Scientific, 
Waltham, MA). Thirty μg of protein were denatured with 2-mercaptoethanol in Laemmli 
buffer, heated at 95 °C for 10 minutes, and then separated on NuPAGE 4-12% SDS-
PAGE (Thermo Fisher Scientific). Proteins were transferred to nitrocellulose 
membranes, blocked for 1 hour with 5% nonfat dry milk-TBST (tris-buffered saline, 
tween-20), then incubated with primary antibody against eNOS (1:1000 in 5% nonfat dry 
milk-TBST, M221 (ab76198) Abcam, Cambridge MA), or GAPDH (1:1000 in 1% BSA-
TBST, #MAB374, EMD Millipore, Billerica, MA) overnight at 4 °C. After washing with 
TBST, membranes were incubated with anti-mouse (for eNOS and GAPDH detection) 
or anti-rabbit (for GLA detection) secondary antibody at (1:15,000 in 1% BSA-TBST). 
Membranes were washed with TBST and incubated with enhanced chemiluminescence 
(Pierce ECL Western Blotting Substrate, Thermo Fisher Scientific). Protein bands were 
detected with film exposure. The film was scanned and protein bands quantified with 
ImageJ Software. 
Statistical analysis 
Data were analyzed by using Prism 7.0 software (GraphPad Software Inc, La Jolla, CA). 
Significance was determined by two-way analysis of variance (ANOVA) with Dunnett's 
or Sidak’s multiple comparisons test. Values are shown as mean ± SEM. Differences 
between groups were considered statistically significant at a P-value of <0.05. 





Two methods of reducing neutral GSLs have different effects on NOS activity 
Previously, it was shown that two different methods, exogenous GLA treatment or 
substrate deprivation with eliglustat treatment, can lower neutral GSL content in GLA(-) 
cells (chapter 2). To determine if diminished NOS activity is due to the absence of 
functional GLA or accumulation of neutral GSLs, these two pharmacological methods 
were used. Cells were treated with either exogenous GLA or eliglustat (20 or 200 nM) 
for 3 days, and then harvested for NOS activity measurements. GLA enzyme treatment 
increased NOS activity in all cells (fig. 3.1), indicating a direct correlation between 
presence of the functional GLA enzyme and functioning NOS. In contrast, treating with 
eliglustat decreased NOS activity in a dose-dependent manner (fig 3.2). 
 
Figure 3.1: Exogenous GLA improves NOS Activity 
GLA(-) cell lines (2, 5, 12, 14) and the WT cell line (17) were treated with 
exogenous GLA (shaded bars), resulting in increased NO production. Dotted line 
indicates WT control (C) normalized to 100%. n=8, ****P<0.0001, ***P<0.001, 




Figure 3.2: Eliglustat treatment reduces NOS activity. 
GLA(-) cell lines (2, 5, 12, 14) and the WT cell line (17) were treated with 
eliglustat (20 or 200 nM) for 3 days, resulting in decreased NO production. 
Results are reported as %17(WT)-vehicle. n=5 ****P<0.0001 compared to 
17(WT) each treatment. 
 
Sepiapterin and methotrexate treatments affect NOS Activity 
A previous study using the anti-GLA siRNA EA.hy926 cell model reported an increase in 
3-nitrotyrosine (Shu, Vivekanandan-Giri et al. 2014), which is a marker indicating the 
presence of reactive nitrogen species and eNOS uncoupling (Heinecke 2002). To 
determine if BH4 supplementation would reverse eNOS uncoupling in GLA(-) cells, cells 
were treated with DMSO vehicle control, or sepiapterin (20 or 200 μM). As expected, 
sepiapterin treatment increased NO production in all clonal cell lines (fig. 3.3). However, 
sepiapterin treatment did not restore NO production to the same level as WT for each 
treatment. In contrast, treating with the DHFR inhibitor, methotrexate, there was a 
decrease in NOS activity (fig. 3.4). The increase in NOS activity seen with sepiapterin 
was confirmed to be biopterin-dependent by treating cells with both sepiapterin and 
methotrexate (data not shown). In the presence of methotrexate, sepiapterin decreases 
BH4 availability by inhibiting GTP cyclohydrolase I (GTPCH), the first step in de novo 




Figure 3.3: Sepiapterin treatment increases NOS activity. Cells were treated 
with sepiapterin (20 or 200 μM) for 18 hours and then harvested for NOS activity 
measurements. Dotted line indicates WT control normalized to 100%. n=4 
****P<0.0001, *P<0.05 compared to 17 (WT) each treatment. 
 
 
Figure 3.4: Methotrexate treatment decreases NOS activity. 
Cells were treated with methotrexate (MTX, 3, 7, or 10 μM) for 18 hours and then 
harvested for NOS activity measurements. Dotted line indicates WT-DMSO 
normalized to 100%. n=6 for DMSO, 3, and 7 μM; n=2 for 10 μM,. ****P<0.0001, 













































Conditioned media from GLA(-) cells increases NOS activity in WT cells 
To determine if GLA(-) cells release a substance into the media that could affect NOS 
activity, a conditioned media experiment was performed. Media was incubated with the 
GLA(-) clone 12 for 3 days, and then transferred to WT (clone 17) cells for 3 days. The 
opposite was also performed. There was ~80% increase in NOS activity in WT cells 
treated with media from GLA(-) cells (fig. 3.5). To explore a possible mechanism for this 
increase, eNOS protein expression was measured by Western blot (fig. 3.6). Incubating 
WT cells with media from GLA(-) media caused ~20% increase in eNOS expression 
compared to treating with cell-free media, which correlates with the trend of increased 
NO production in this condition. In addition, GLA(-) cells incubated with GLA(-) media 
from separately plated cells showed about a 2-fold increase of eNOS protein 
expression. 
 
Figure 3.5: GLA(-) media increases NOS activity in WT cells. 
Cells were treated with media that was incubated with WT or GLA(-) cells, or no 
cells as a control (cell-free media). There is a significant increase in [3H]L-
citrulline production in WT cells that were incubated with media from GLA(-) cells. 






Figure 3.6: GLA(-) media increases eNOS protein expression in WT cells. 
Cells were treated with media that was incubated with WT or GLA(-) cells, or no 
cells as a control (cell-free media). There is a significant increase in eNOS 
expression in WT cells and GLA(-) cells that were incubated with media from 
GLA(-) cells. eNOS expression is also increased GLA(-) incubated with media 
from GLA(-) cells. n=2-6. ***P<0.001, **P<0.01, *P<0.05 when compared to cell-
free media or WT media as indicated. 
 
Lyso-Gb3 inhibits NOS activity 
Previously, it was determined that GLA(-) EA.hy926 cells have elevated 
globotriaosylsphingosine (lyso-Gb3) compared to WT cells (chapter 2). It has also been 
shown that GLA(-) cells have decreased NOS activity. To determine if there is a 
correlation between presence of lyso-Gb3 and NOS activity, lyso-Gb3 (250 or 500 nM) 
was added to cell culture media for 3 days, and NOS activity was measured in cell 
lysates. The concentrations used are within the range reported to increase smooth 















NOS activity compared to cells treated with DMSO or glucosylsphingosine (GlcSph) 
(data not shown). 
To directly assess the effect of lyso-Gb3 on eNOS, lyso-Gb3, GlcSph, or Gb3 were 
added to the NOS reaction mixture for a final concentration of 10-60 μM lyso-Gb3 in the 
reaction. NOS activity is severely inhibited by lyso-Gb3, and to a lesser extent, GlcSph 
(fig. 3.7). Gb3 in the reaction mixture only slightly affects NOS activity. There is an 
increase in activity at the 50 pmol/μg protein concentration for both lyso-Gb3 and Gb3. 
The experiment was repeated with GLA(-) clonal cell line 12 (fig. 3.8). 
To determine if the effect seen is due to a direct interaction of the lipid and protein, cell 
lysates were incubated with lyso-Gb3 or GlcSph on ice for 1 hour before adding the 
other reagents into the NOS reaction mixture. Lyso-Gb3 and GlcSph inhibit the reaction 
in this condition (fig. 3.9). In GLA(-) lysates, the effect is not as drastic, presumably due 
to the low activity with DMSO-control (~50% WT-DMSO-control). 
 
Figure 3.7: Lipids in NOS reaction inhibit activity. 
The NOS reaction was performed with different amounts of Lyso-Gb3, GlcSph, 
and Gb3 in the reaction mixture. Each reaction contained 10 μg of protein from 
clone 17 (WT) lysates. Results are reported as %DMSO. n=3 ****P<0.0001, 





















Figure 3.8: Lyso-Gb3 inhibits NOS activity in a dose-dependent manner. 
The NOS reaction was performed with different amounts of Lyso-Gb3 in the 
reaction mixture. Each reaction contained 10 μg of protein from WT or GLA (-) 
lysates. Results are reported as %WT-DMSO (dotted line).n=3. ****P<0.0001, 
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Figure 3.9: Preincubation of cell lysates with lyso-lipids inhibits NOS 
activity. 
10 μg of protein from WT and GLA (-) cells were incubated with different amounts 
of lyso-Gb3 or GlcSph for 1 hour before beginning the NOS reaction. Results are 
reported as %WT-DMSO (dotted line). n=3. ****P<0.0001, ***P<0.001 compared 


























Presence of inhibitor in lysates from GLA-deficient cells 
To determine the possibility that lyso-Gb3 or another substance in GLA(-) cell lysates 
inhibits NOS activity, the NOS assay was performed with 10 μg protein per reaction, 
made up of combinations of cell lysates from WT and GLA(-) cells in various 
proportions. The expected results are calculated based on the results of 10 μg of WT or 
GLA (-) – only samples. There is a trend of experimental values being lower than 
expected values, but only one combination reached statistical significance (8 μg GLA (-) 
and 2 μg WT protein, p=0.0132). 
 
Figure 3.10: GLA (-) cell lysates decrease activity of WT cell lysates. 
NOS reactions were setup with a total of 10 μg protein lysate in each reaction, 
containing different proportions of WT and GLA (-) lysates. Expected values are 
calculated from experimental results of 10 μg homogenous samples. n=3. 




















































































Patients with Fabry disease have an increased incidence of vasculopathy compared to 
the non-Fabry population (Sims, Politei et al. 2009). GLA deficiency causes 
accumulation of globo series glycosphingolipids (GSLs), most notably in vascular 
endothelial cells (Desnick, Ioannou et al. 2001). Past studies indicate that defects of 
vascular dysfunction can be localized to the endothelium, and endothelial nitric oxide 
synthase (eNOS) uncoupling may be the basis for impaired vascular function (Shu, Park 
et al. 2009, Shu, Vivekanandan-Giri et al. 2014). To further investigate biochemical 
changes due to GLA deficiency, this study used GLA(-) EA.hy926 cells to address 
whether eNOS uncoupling is due to accumulation of GSLs, limited availability of the 
eNOS cofactor, tetrahydrobiopterin (BH4), or elevated globotriaosylsphingosine (lyso-
Gb3). 
The primary treatment method for Fabry disease is enzyme replacement therapy (ERT) 
with recombinant GLA. Substrate deprivation is an alternative approach to reducing 
accumulation of globo-series GSLs, where a small molecule inhibitor of 
glucosylceramide (GlcCer) synthase prevents the de novo synthesis of downstream 
GSLs, including lactosylceramide (LacCer), globotriaosylceramide (Gb3), and 
globotetraosylceramide (Gb4) (Abe, Arend et al. 2000, Abe, Gregory et al. 2000). A 
previous in vitro experiment performed with mouse aortic endothelial cells (MAECs) 
from Gla-knockout mice reported that treating cells with recombinant GLA or a GlcCer 
synthase inhibitor reduced the accumulation of Gb3 (Shu, Murphy et al. 2005). Similarly, 
treating CRISPR/Cas9 GLA(-) EA.hy926 cells with exogenous GLA or the GlcCer 
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inhibitor, eliglustat, decreased the accumulation of globo-series GSLs (figs 2.10 and 
2.11). 
Although both exogenous GLA and eliglustat reduce neutral GSLs, they have different 
mechanisms of action. GLA decreases the level of its primary substrate, Gb3, and 
decreases of LacCer and Gb4 levels are secondary (chapter 2). On the other hand, 
eliglustat, a GlcCer synthase inhibitor, prevents the synthesis of GlcCer, and 
subsequently of LacCer, Gb3, and Gb4. We report here that eliglustat treatment 
decreases NOS activity, even in WT cells (fig.3.2). These results are in agreement with 
a previous study where treatment of MAECs from Gla-deficient mice with the GlcCer 
synthase inhibitor, D-threo-ethylenedioxyphenyl-2-palmitoylamino-3-pyrrolidinopropanol, 
did not improve NOS activity, although Gb3 was cleared from cells (Shu, Park et al. 
2009). In contrast, treating EA.hy926 cells with exogenous GLA increased NOS activity, 
in both GLA(-) and WT cells (fig. 3.1). The opposite effects of two methods of reducing 
GSLs on NOS activity suggests that restoring GLA activity is more important than 
decreasing the level of GSLs for restoring eNOS function. 
Several experimental models of Fabry disease have suggested that eNOS dysfunction 
is the basis for vasculopathy that occurs in many patients with Fabry disease (Eitzman, 
Bodary et al. 2003, Bodary, Shen et al. 2005, Park, Whitesall et al. 2008, Shu, Park et 
al. 2009, Shu, Vivekanandan-Giri et al. 2014). eNOS uncoupling occurs when there is 
improper flow of electrons from the reductase domain of eNOS, to the oxidase domain. 
Normally, NADPH-derived electrons are used to convert L-arginine and molecular 
oxygen to NO and L-citrulline. In the case of eNOS uncoupling, however, the electrons 
are not transferred to L-arginine and are instead transferred to O2, forming superoxide 
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instead of NO (Vasquez-Vivar, Kalyanaraman et al. 1998, Xia, Tsai et al. 1998). 
Superoxide then reacts with NO to produce a reactive nitrogen species, peroxynitrite 
(ONOO-). ONOO- rapidly oxidizes BH4 to the inactive form, dihydrobiopterin (BH2) 
(Milstien and Katusic 1999). BH4 is a cofactor of eNOS that keeps eNOS in the active, 
homodimer form (Rodriguez-Crespo, Gerber et al. 1996). A decrease in BH4 availability 
causes further uncoupling. 
Lower BH4 availability due to a pro-oxidant state has been described in the more 
common diseases, diabetes and hypertension (Landmesser, Dikalov et al. 2003). 
Supplementation with BH4 improves NOS function in patients with diabetes (Heitzer, 
Krohn et al. 2000), chronic smokers (Heitzer, Brockhoff et al. 2000, Ueda, Matsuoka et 
al. 2000), hypertension (Hong, Hsiao et al. 2001), and hypercholesterolemia (Stroes, 
Kastelein et al. 1997). In this study, we have reported that GLA(-) cells also have lower 
BH4 availability, and BH4 supplementation improves NOS function. BH4 levels can be 
pharmacologically modulated with sepiapterin and methotrexate. Sepiapterin is the 
substrate for the first step in the salvage pathway that regenerates BH4. Methotrexate is 
an inhibitor of DHFR, thus inhibiting regeneration of BH4 from BH2 (fig. 1.4). These 
reagents were used in this study to show that GLA(-) cell have limited BH4 availability, 
and increasing BH4 availability improves NOS activity. Treating cells with sepiapterin 
significantly increases NOS activity in GLA(-) cells (fig. 3.3). On the other hand, treating 
with methotrexate decreases NOS activity in GLA(-) cells (fig. 3.4) to a level that is not 
significantly different than WT with the same methotrexate treatment.  
A recent study (Shen, Arning et al. 2017) reported that BH4 was decreased in the heart 
and kidney of Fabry mice, and that Gb3 levels were inversely correlated with BH4 levels 
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in tissues. The study also reported decreased glutathione levels in Fabry mouse 
tissues. These results correlate with the present study. Increasing BH4 availability in 
GLA(-) cells increased NOS activity, and GLA(-) cells have less glutathione availability 
(fig. A.1). The same study also reported that restoring GLA activity in the Fabry mice for 
6 months did not improve BH4 availability, but treating mice with a GlcCer synthase 
inhibitor (GZ161) for 6 months did (Shen, Arning et al. 2017). These results conflict with 
results from our study as eliglustat treatment decreased NOS activity. Although we did 
not measure BH4 levels, if BH4 levels were improved with eliglustat, then we would 
have expected to observe an increase in NOS activity. 
Previous results indicated that lyso-Gb3 is elevated in cell lysates from GLA(-) cells (fig. 
2.14). We now have shown that lyso-Gb3 can inhibit NOS activity (figs. 3.7, 3.8, 3.9). A 
discrepancy between the two studies is the higher concentration of lyso-Gb3 in the NOS 
reaction needed to elicit a response. A possible explanation is that it is not known where 
in the cell lyso-Gb3 is concentrated. eNOS is active when it is localized to caveolae in 
the plasma membrane (Shaul, Smart et al. 1996). Caveolae are rich in GSLs. Lyso-
GSLs may tend to accumulate in acidic compartments (Ferraz, Marques et al. 2016). It 
is unclear if they are found in the plasma membrane where eNOS is active. It remains to 
be determined if the concentration of lyso-Gb3 in the NOS inhibition experiment is 
physiologically relevant. Also, other lipids, such as LacCer or Gb4, should be tested in 
this system to better design a possible a structure-activity relationship between lipids 
and NOS activity. GlcSph, another lyso lipid, also inhibits NOS, but at a higher 
concentration than lyso-Gb3. No change in NOS activity was observed when adding 
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lyso-Gb3 or GlcSph to the cell culture. It is possible that the reagents are not stable in 
the cell culture media, or that they are not getting into cells. 
Treatment that improves endothelial function would be useful for managing life-
threatening complications of Fabry disease. In this study, mechanisms are uncovered to 
improve NOS activity in the setting of GLA deficiency. NOS activity is increased upon 
treating cells with GLA, but not with eliglustat (figs. 3.1 and 3.2). This indicates that GLA 
activity, not lower GSL levels, is critical for maintaining proper NOS activity. Another 
finding of this study was that increasing BH4 availability improves NOS activity in the 
setting of GLA deficiency (fig. 3.3). GLA deficiency may be causing a decrease in BH4 
that is corrected upon supplementation with the precursor of BH4, sepiapterin. It 
remains to be seen whether BH4 levels correlate with 3-nitrotyrosine, a marker of eNOS 
uncoupling in Fabry disease (Shu, Vivekanandan-Giri et al. 2014).  
We observed was that GLA(-) cells release a substance into cell culture media that 
increases NOS activity in WT cells (fig. 3.5). This was surprising because it was 
expected that GLA(-) cells secrete a substance, possibly lyso-Gb3, that would decrease 
NOS activity. The increase of NOS activity is partially due to increased eNOS 
expression in these samples. However, further investigations assessing the expression 
of another NOS isoform, inducible NOS (iNOS), need to be performed to explain the 
increase of NOS activity.  
Finally, lyso-Gb3, which is found to be elevated in Fabry disease, inhibits NOS activity 
(figs. 3.7, 3.8, and 3.9). This is further evidence that lyso-Gb3 is not just a biomarker of 
Fabry disease, but is involved in the pathogenesis of the disease. Published reports 
indicate that lyso-Gb3 promotes smooth muscle cell proliferation, which may contribute 
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to the increased intima-media thickening seen in patients (Aerts, Groener et al. 2008), 
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Chapter 4: Discussion 
Summary 
In this thesis I have reported potential mechanisms of endothelial nitric oxide synthase 
(eNOS) uncoupling in Fabry disease. In chapter 2, I detail the process of using 
CRISPR/Cas9 gene editing to obtain multiple single-cell colonies that have a frameshift 
mutation in Gla and do not express α-galactosidase A (GLA, referred to as GLA(-) 
cells). These cells have less NOS activity compared to the wild type (WT) GLA control. 
Globotriaosylsphingosine (lyso-Gb3) was found to be the lipid that is consistently 
elevated in both siRNA and CRISPR/Cas9 models of GLA deficiency. The purpose of 
using CRISPR/Cas9 to obtain GLA(-) cells was to be able to investigate the effects of 
GLA deficiency in an endothelial cell model of Fabry disease that could be continually 
passaged without further treatment, and maintain the Fabry phenotype of elevated 
glycosphingolipids (GSLs) and decreased NOS activity. In chapter 3, I report 
mechanisms of eNOS uncoupling in GLA(-) cells: restoration of GLA activity, and not 
necessary reduction of GSLs, is important for proper NOS activity; GLA(-) cells have 
limited tetrahydrobiopterin (BH4) availability, and BH4 supplementation improves NOS 
activity in GLA(-) cells; and lyso-Gb3 may be inhibiting NOS activity directly. 
Furthermore, I report that GLA(-) cells release a substance into cell culture media that 
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increases NOS activity in WT cells, but the increase in activity is not completely due to 
increased eNOS expression. 
GLA deficiency affects neutral GSL levels 
The EA.hy926 cell line was chosen for this study because previous work had shown 
that siRNA-mediated GLA knockdown caused an accumulation of globotriaosylceramide 
(Gb3) (Shu, Vivekanandan-Giri et al. 2014), which is what is seen in Fabry patients and 
other models of Fabry disease (Sweeley and Klionsky 1963, Ohshima, Murray et al. 
1997).  
Surprisingly, GLA(-) EA.hy926 cells, induced by CRISPR/Cas9 gene mutation, have a 
different lipid profile compared to siRNA-induced GLA(-) EA.hy926 cells (figs 2.5, 2.6, 
2.7, 2.8). Notably, the CRISPR/Cas9 GLA(-) cells do not accumulate Gb3, the primary 
substrate for GLA. This finding was explained by observing that the CRISPR/Cas9 
GLA(-) cells have a significant accumulation of globotetraosylceramide (Gb4), whereas 
3-6 day anti-GLA siRNA treatment caused only a moderate increase of Gb4. 
Because cell lines were expanded from a single cell, it was not possible to measure lipid 
content until each single cell colony had millions of cells. Therefore, it is possible that 
the CRISPR/Cas9 GLA(-) cells had an increase in Gb3 during the first few days after 
the initial Gla disruption post-CRISPR/Cas9 transfection, but after several passages, 
Gb4 became the prominent GSL. 
Despite differences of Gb3 and Gb4 accumulation, both the CRISPR/Cas9 and siRNA 
models of GLA deficiency have decreased NOS activity (fig. 2.15 and (Shu, 
Vivekanandan-Giri et al. 2014)) and elevated lyso-Gb3 (fig. 2.14). Our study supports 
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data indicating that lyso-Gb3, not Gb3, is a biomarker for Fabry disease (Smid, van der 
Tol et al. 2015). Lyso-Gb3 level in human plasma correlates with GLA deficiency, and is 
more consistently increased in heterozygous females than is Gb3. Furthermore, lyso-
Gb3 levels go down post-enzyme replacement therapy (ERT) (van Breemen, Rombach 
et al. 2011). 
GSLs and caveolae 
Caveolae are structures on the plasma membrane that were first described in the 1950s 
(Palade 1953, Yamada 1955), and are found in many mammalian cells, such as 
adipocytes, muscle cells, and endothelial cells (Parton and Simons 2007). They were 
later discovered to be involved in the endocytosis of large molecules from the 
extracellular space, and important for many signaling processes (Lisanti, Tang et al. 
1995, Pelkmans and Zerial 2005). Caveolae are rich in GSLs and cholesterol compared 
to the surrounding plasma membrane (Ortegren, Karlsson et al. 2004). GSLs in the 
plasma membrane have been shown to regulate signaling molecules, like receptor 
tyrosine kinases (Bremer, Schlessinger et al. 1986), phospholipase C (Shu, Lee et al. 
2002) and Src kinases (Shu and Shayman 2003). Prior to a study in the Shayman group 
indicating that Gb3 accumulates in caveolae (Shu, Lee et al. 2002), the idea that 
sphingolipids can accumulate outside of the lysosome in lysosomal storage diseases 
was not well studied. A later study found that high molecular weight oligomers of 
caveolin-1 are reduced in mouse aortic endothelial cells (MAECs) isolated from Gla-
knockout mice (Shu, Park et al. 2009). 
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The caveolin-1 protein is mainly in the oligomeric form, and is essential for caveolae 
formation (Drab, Verkade et al. 2001). Caveolin-1 acts as a scaffold for signaling 
molecules in caveolae, like eNOS which, upon palmitoylation, gets trafficked to the 
plasma membrane by caveolae, (Garcia-Cardena, Oh et al. 1996). Under conditions of 
reduced tetrahydrobiopterin (BH4) availability, caveolin-1 associates with eNOS to 
inhibit eNOS and prevent eNOS-derived superoxide formation (Karuppiah, Druhan et al. 
2011). In chapter 3, I reported that decreased NOS activity in GLA(-) cells is likely due 
to decreased BH4 availability. These results are supported by a recent report that Fabry 
mice have decreased BH4 in the heart, and plasma BH4 is decreased in both Fabry 
mice and Fabry patients (Shen, Arning et al. 2017). Considering the association of BH4, 
eNOS, and caveolin-1, it is likely that in the setting of GLA-deficiency, BH4 deficiency 
causes eNOS uncoupling and superoxide production that is not attenuated by caveolin-
1 because of the disruption of caveolae in the setting of GLA-deficiency.  
Future directions 
Which lipids directly or indirectly inhibit NOS activity? 
In this study, I showed that lyso-Gb3 dose-dependently inhibits eNOS activity (fig. 3.7, 
3.8, and 3.9). GlcSph, another lyso-lipid, also inhibits NOS activity, but at higher 
concentrations. Gb3 only slightly, if at all, seemed to affect NOS activity. To build on this 
preliminary work, the effect of additional GSLs and lyso-lipids on NOS activity should be 
evaluated. Other lipids to test include ceramide, lactosylceramide (LacCer), 
globotetraosylceramide (Gb4), and lactosylsphingosine. A structure-activity relationship 
would be useful to determine how lyso-Gb3 interacts with eNOS. 
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Creating a cell library of deficiencies of globo-series GSL catabolic and anabolic 
enzymes using CRISPR/Cas9 
To determine which GSLs contribute to eNOS uncoupling, it would be useful to develop 
groups of cells that lack expression of genes along the catabolic and anabolic pathways 
of neutral GSLs. Some metabolic genes in the globo-series GSL pathway are shown in 
figure 4.1. It is possible that just like in the case of Gla and Gb3, a specific enzyme 
knockout may not lead to accumulation of its substrate. However, it is expected that 
knockouts of each of these genes would results in a different lipid profile that can be 
correlated with NOS activity. The results would indicate if a specific lipid, or group of 
lipids, is causing eNOS uncoupling. Furthermore, eNOS uncoupling could be correlated 
with either a specific loss of GLA activity, or another GSL metabolic enzyme. In a 
previous study from the Shayman group (Shu, Vivekanandan-Giri et al. 2014), siRNA 
was used to silence GLA or GBA in EA.hy926 cells. Only anti-GLA siRNA treatment 
resulted in decreased NOS activity and increased 3-nitrotyrosine production (marker for 
eNOS uncoupling). 
 
Figure 4.1: Globo-series GSL catabolic and anabolic genes. Genes that 
synthesize and degrade GSLs are listed. Fabry disease arises from mutations in 
GLA. Gaucher disease, another lysosomal storage disease, arises from 
mutations in GBA. GlcCer: glucosylceramide; LacCer: lactosylceramide; Gb3: 





Why is Gb4, not Gb3, elevated in GLA-deficient EA.hy926 cells? 
A surprising finding in the CRISPR/Cas9 GLA(-) cells was the accumulation of Gb4, 
instead of Gb3, which is the primary substrate of GLA. One way to address why Gb4 is 
elevated in CRISPR/Cas9 GLA(-) cells is to determine if expression of Gb4 synthase 
(B3GALNT1) is increased. I performed a pilot study where I measured mRNA 
expression of B3GALNT1 in GLA(-) EA.hy926 cells (qRT-PCR methods described in 
appendix). The results show an increase in expression of B3GALNT1 in GLA(-) clonal 
cell lines, 5, 12, and 14 (fig. 4.2). Future studies should investigate changes in mRNA 
expression of other GSL metabolic genes (fig. 4.1). There is a possibility that the Gb4 
catabolic enzyme, hexosaminidase (HEXA and HEXB), is downregulated in EA.hy926 
cells, which would explain the higher level of Gb4 in the absence of GLA-mediated Gb3 
catabolism. 
 
Figure 4.2: GLA(-) cells have increased B3GALNT1 mRNA expression. Cells 
were grown to confluency, harvested, and mRNA was extracted. After reverse 
transcriptase reaction, cDNA was used for real-time qRT-PCR measurement for 
expression of B3GalNT1, which encodes the enzyme, Gb4 synthase. Expression 
levels were normalized to GAPDH and WT control and presented as fold change. 
Clonal cell lines 5, 12, and 14 had a significant increase in mRNA expression for 
β3GalNT1. This may explain the elevated level of Gb4 in lipid extracts from these 
cell lines. n=6, ****P<0.0001, **<0.01 compared to clone 17(WT) control. For 
method, please refer to the appendix. 
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How do GLA and eliglustat treatments affect BH4 levels? 
GLA and eliglustat treatment have opposite effects on NOS activity (figs. 3.1 and 3.2), 
although they both reduce neutral GSL levels (figs. 2.10 and 2.11). To explain one of 
the mechanisms of this observation, it would be useful to determine how GLA and 
eliglustat affect BH4 levels. GTP cyclohydrolase 1 (GTPCH1) catalyzes the first step of 
de novo BH4 synthesis, and is the rate limiting step (fig 1.4). To determine the reason 
for deficient BH4, GTPCH1 expression should be determined in GLA(-) cells. A recent 
study reported that GTPCH1 protein expression was downregulated in Fabry mouse 
heart, and treatment with a GlcCer synthase inhibitor (GZ161) increased GTPCH1 
protein expression (Shen, Arning et al. 2017). Considering these results and the results 
from our own experiments, if treatment with the GlcCer synthase inhibitor eliglustat 
increased GTPCH1 protein expression in EA.hy926 cells, then we would have observed 
an increase in NOS activity. However, in our study, eliglustat treatment decreased NOS 
activity. Determining changes in GTPCH1 expression could help explain the 
discrepancy between the two studies. 
Other NOS isoforms in EA.hy926 cells 
The work in this thesis focused primarily on the endothelial isoform of NOS, eNOS. 
Another isoform that is pertinent to vasculopathy in Fabry disease is the inducible NOS 
(iNOS) isoform. iNOS is not constitutively expressed like the endothelial and neuronal 
NOS isoforms, but expression is induced by inflammatory cytokines, and its activity is 
Ca2+-independent (Aktan 2004). While eNOS has a protective role in maintaining a 
functioning vascular endothelium and preventing the development of atherosclerosis, 
increased iNOS expression is found in many inflammatory diseases, including 
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atherosclerosis (Luoma, Stralin et al. 1998). In a study evaluating the development of 
atherosclerosis in Fabry mice, it was found that Gla-deficient mice bred on an ApoE(-) 
background had increased iNOS immunostaining in atherosclerotic plaques (Bodary, 
Shen et al. 2005). Because the EA.hy926 cells I am working with are derived from 
endothelial cells (human umbilical vein cord cells), it is presumed that the major NOS 
isoform expressed is eNOS. However, a few studies report that EA.hy926 cells do in 
fact express iNOS under inflammatory conditions (Toma, Stancu et al. 2011, Lee, Wang 
et al. 2016). 
In chapter 3, I reported that WT cells incubated with cell culture media that was 
previously incubated with GLA(-) cells for 3 days increased NOS activity by ~80%, but 
only increased eNOS protein expression by ~25%. Follow up studies to the conditioned 
media experiment should include Western blot analysis of iNOS protein expression. If 
iNOS expression is increased in WT cells treated with GLA(-) media, it could explain the 
large increase of NOS activity, while there is only a small increase of eNOS expression. 
Furthermore, iNOS expression should be evaluated in all CRISPR/Cas9 clonal cells 
lines. If iNOS protein expression is increased in GLA(-) clone 2, it would help explain 
why NOS activity in clone 2 cell lysates is consistently higher than the other GLA(-) 
clones (fig. 2.15), but has similar lyso-Gb3 and total glutathione levels to the other 
GLA(-) clones (figs. 2.14 and A.1).  
LAESI-MS method of identifying and quantifying GSLs 
High performance thin layer chromatography (HPTLC) is the method I used to measure 
neutral GSLs in chapter 2. The basis for TLC is separation of molecules based on 
polarity. It is a robust and relatively inexpensive method to rapidly analyze lipid content 
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(Skipski 1975, van Echten-Deckert 2000). Known standards are developed alongside 
samples, but the exact identity of a species cannot be confirmed by TLC alone. Many 
groups have developed methods to scrape the silica of the lipid of interest, elute the 
lipid, and analyze the lipid by mass spectrometry (MS) (Meisen, Peter-Katalinic et al. 
2004). MS gives detailed information about the structure of the lipid, especially the 
carbon length of the ceramide moiety of the GSL. However, this indirect method of 
combing TLC and MS is time consuming and can lead to loss of material. 
A new method that can directly analyze lipids on a TLC place is laser ablation with 
electrospray ionization (LAESI) (Nemes and Vertes 2007). Samples are applied to a 
TLC plate, developed in the appropriate solvent systems, and lipids are visualized with 
the nondestructive agent, primuline (Skipski 1975). The spot of interest is wetted (eg 
with water) and a laser is directed to the location. Analytes are transferred into a mass 
spectrometer through desorption/ionization. I have done some pilot studies where I 
analyzed Gb3 and Gb4 in EA.hy926 cells with this method7. This method confirmed the 
identity of Gb3 and Gb4 in samples based on mass (data not shown). More assays 
need to be done in order to identify differences in ceramide species among the clonal 
cell lines and if GLA deficiency causes changes in GSLs with a specific carbon length 
Conclusions 
Studying a rare disease arising from a single genetic defect provides a window of 
opportunity to gain understanding of normal physiology. Considering the vast number of 
questions left to answer in biology, there is always a need to develop better models to 
                                            
7 LAESI-MS performed in collaboration with Ashootosh Tripathi in the Sherman group. 
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study diseases. The intention of the work presented in this dissertation was to do just 
that – develop an endothelial cell line with a permanent absence of GLA protein 
expression to better understand eNOS uncoupling in Fabry disease. Previous studies 
had reported Gb3 accumulation as a major contributor to the pathology of Fabry 
disease, but the CRISPR/Cas9 model of GLA-deficiency I developed and analyzed 
indicated that eNOS uncoupling still occurs even when Gb3 is not elevated. I also report 
that eNOS uncoupling in the setting of GLA deficiency may be due to decreased 
availability of the eNOS cofactor, BH4, and by the presence of lyso-Gb3. 
The only approved therapeutic for Fabry disease in the United States, enzyme replace 
therapy, was approved for use less than 20 years ago. Although this treatment has 
improved the lives of patients, it does not completely reverse disease progression, and 
there remains a need for better therapeutics. Understanding the mechanism behind one 
of the complications of the disease, endothelial dysfunction, is a step towards improving 
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Quantitative real-time polymerase chain reaction (qRT-PCR) method for 
measuring Gb4 Synthase expression 
Total cellular RNA was isolated from 3 x 106 cells using the RNeasy Plus Mini Kit 
(Qiagen, Valencia, CA). The setup for the reverse transcriptase (StepOne Real-Time) 
reaction was: 10 μg RNA, 10x buffer (20 μL), 25x dNTP (8 μL), 10x random primers 
(20μL), reverse transcriptase (10 μL), RNase inhibitor (10 μL), and water, in 200 μL total 
volume. The reaction was carried out as follows: 25°C 10 min, 37°C 120min, 85 °C 5 
sec. 
The primers and RT-PCR program were based on those reported for β1,3-N-
acetylgalactosaminyltransferase (B3GALNT1) and GAPDH (Schweppe, Bielaszewska 
et al. 2008). Primers (Table A.1) were purchased from ThermoFisher Scientific. Each 
reaction had 2 μL cDNA, 12.5 μL SYBRGreen (Qiagen), 1.5 μL of each forward and 
reverse primer (0.3 μM). The RT-PCR cycle was performed on an Applied Biosystems 
StepOne™ Real-Time PCR instrument (ThermoFisher Scientific), and results quantified 
with the StepOne™ Software. The PCR cycle was: 94 °C 3 min 30 sec, 30 cycles: 94 °C 
15 sec, 63 °C 30 sec, 72 °C 1 min; 72 °C 10 min. The 125 bp product for B3GALNT1, 
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and 94 bp product for GAPDH verified by electrophoresis on ethidium bromide stained 
4% agarose gels. 









Table A.1: qRT-PCR primer sequences. Genes and NCBI Reference sequence 
identification; Forward (F), and reverse (R) nucleotides used to quantify gene 
expression in qRT-PCR. B3GALNT1: Β1,3-N-acetylgalactosaminyltransferase 
(β1,3-Gal-NAcT, EC 2.4.1.79; GenBank accession no. Y15062).  
 
GLA-deficient cells have less glutathione availability 
Total glutathione (GSH) was measured in cells using the Glutathione Assay Kit 
(Cayman Chemical) according to manufacturer’s instructions. Cells were harvested and 
lysed in RIPA buffer. GSH is significantly lower in GLA(-) cells (fig A.1). GSH is the most 
abundant endogenous antioxidant. These results are in agreement with data reporting 
increased oxidant production in EA.hy926 cells treated with anti-GLA siRNA (Shu, 
Vivekanandan-Giri et al. 2014), and a recent study reporting decreased total GSH in 




Figure A.1: GLA-deficient cells have less total glutathione. 
Total glutathione (GSH) was measured in cells. GLA(-) clonal cell lines, 2, 5, 12, 
and 14 have significantly lowered GSH availability compared to 17(WT). n=8 
****p<.0001 compared to 17(WT). 
 
Experiments performed with CRISPR/Cas9 – Exon 2 targeted GLA-deficient cells 
 
Figure A.2: GLA Activity in CRISPR/Cas9-Exon 2 GLA(-) cell lines. GLA 
activity was measured with methods described in chapter 2. GLA(-) clonal cell 
lines 8, 14, 18, and 27 have negligible GLA activity compared to the 22(WT) 
control clonal cell line. n=6. Results correlate with CRISPR/Cas9 Gla-Exon 1 
edited cells (fig. 2.1). 
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Figure A.3: CRISPR/Cas9-Exon 2 GLA(-) cell lines have no change in Gb3 
accumulation. Neutral GSLs were isolated and analyzed by TLC with cupric 
sulfate charring as described in chapter 2. There is no significant change in Gb3 
accumulation in GLA(-) cells compared to the WT control (22). LacCer is 
diminished in GLA(-) cells. These results correlate with that of CRISPR/Cas9 
Gla-exon 1 edited clonal cell lines (fig 2.6). n=3-6. **P<0.01, *P<0.05 compared 
to 22(WT). 
 























Figure A.4: CRISPR/Cas9-Exon 2 GLA(-) cell lines accumulate Gb4. Neutral 
GSLs were isolated and analyzed by TLC with orcinol-sulfate charring as 
described in chapter 2. GLA(-) clonal cell lines, 8, 14, and 18 have significantly 
increased amounts of Gb4 compared to 22(WT). GLA(-) clone 27 has no 
significant change in Gb4 or LacCer, but has slightly elevated Gb3 compared to 
22(WT) (p=0.0590). Results are comparable to CRISPR/Cas9 Gla-Exon 1 edited 
clonal cell lines (fig. 2.7). n=3-12****P<0.0001, ***P<0.001, **P<0.01, *P<0.05 
when compared to 22(WT). 







































Figure A.5: CRISPR/Cas9-Exon 2 GLA(-) cell lines have decreased NOS 
activity. NOS activity was measured as described in chapter 2. GLA(-) clonal cell 
lines, 8, 18, and 27 have decreased NOS activity compared to 22(WT). GLA(-) 
clonal cell line 14 has elevated NOS activity, but is not statistically significant. 
These results correlate with CRISPR/Cas9 Gla-exon 1 edited cells (fig 2.15).  
n=8. **P<0.01 when compared to 22(WT). 
 
 
Figure A.6: CRISPR/Cas9-Exon 2 GLA (-) cell lines have decreased eNOS 
expression. Western blot was performed as described in chapter 2. GLA(-) 
clonal cell lines, 8, 18, and 27 have decreased eNOS expression compared to 
22(WT). GLA(-) clonal cell line 14 has no change of eNOS expression. These 
results correlate with CRISPR/Cas9 Gla-exon 1 edited cells (fig 2.16). n=4. 
***P<0.001 when compared to 22(WT). 




















Figure A.7: Exogenous GLA treatment improves NOS activity in 
CRISPR/Cas9-Exon 2 GLA(-) cell lines. Exogenous GLA treatment and NOS 
assay were performed as described in chapter 3. These results correlate with 
CRISPR/Cas9 Gla-exon 1 edited cells (fig 3.1). n=2. ***P<0.001, ****P<0.0001 



































































Correlation of μg protein in NOS assay to cpm measurement 
 
Figure A.8: NOS reaction is dependent on μg protein in reaction. NOS 
reaction was performed as described in chapter 2 and 3, but with different 
amounts of lysates from WT or GLA(-) cells. NOS assays described in chapters 2 
and 3 were performed with 5-10 μg protein. The cell lysates in this figure 
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